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 There is an increasing need for justification of medical nutrition therapy given by 
the dietitian.  With health care costs escalating rapidly, practitioners need to demonstrate 
that they can improve patient outcomes.  Outcomes research provides a practical 
approach to health care evaluation.  The purpose of this study is to determine if the 
amount of involvement by a registered dietitian with leukemia patients on total parenteral 
nutrition (TPN) improves outcomes.  The outcomes included in this study were 1) length 
of inpatient stay, 2) length of TPN administration, 3) percentage of energy needs met by 
the TPN, 4) weight change, and 5) visceral protein status measured by serum albumin on 
admission and discharge.  Dietitian involvement was defined as the percentage of 
recommended follow up documentations achieved (meeting the protocol of 
 ii
documentation every four days).   A retrospective study of 115 medical records from 
adult patients with leukemia was conducted.  The types of leukemia included were, acute 
myelogenous leukemia, acute lymphocytic leukemia, chronic myelogenous leukemia, and 
chronic lymphocytic leukemia.  Data was analyzed using SPSS statistical analysis 
software.  Timely dietitian involvement was indirectly correlated with length of days on 
TPN (r = -0.211, p = 0.026), and positively correlated with percentage of energy needs 
met (r = 0.028, p = 0.012).  No significant associations were observed for length of 
inpatient stay, weight change, or visceral protein status.  These results suggest that the 
dietitian can improve patient outcomes by decreasing the number of days on TPN as well 
as meeting essential energy requirements. This study demonstrates dietitian intervention 
produced better patient outcomes as well as potential cost savings to the institution.   
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 Introduction 
  Leukemia is a type of cancer of the bone marrow and blood affecting both adults 
and children.  In the U.S. in 2001, it was estimated that there would be 30,200 new cases 
of leukemia (The Leukemia and Lymphoma Society 2001a).   
 In cancer patients, the course of the disease and treatment places them at 
nutritional risk.  Proper nutrition is essential for cancer patients.  Enough calories should 
be consumed so that the body does not have to use reserves such as protein stores (Bloch 
1998).  A form of nutrition support called total parenteral nutrition (TPN) may be 
indicated in certain circumstances to maintain an adequate nutritional state.  TPN is an 
intravenous feeding in which a solution of dextrose, amino acids, fat, and vitamins and 
minerals are infused into the patient.   
 Providing safe and effective parenteral nutrition was the means for starting a 
multidisciplinary approach to nutrition support.  The nutrition support team consists of a 
physician, registered dietitian, nurse, and pharmacist, with each team member assessing 
the patient according to his or her discipline (Wesley 1995).  The dietitian’s role includes 
conducting a nutrition assessment.  A nutrition assessment generally consists of 
anthropometric, biochemical, clinical, and dietary information.  After evaluation of this 
information and data from the other health disciplines, the dietitian develops a care plan, 
and follows through with intervention and evaluation (Posthauer et al. 1994).             
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Rationale for the Study 
 
Two hospitals that are part of a health system in a large metropolitan area in the 
Midwest were used in this study.  To maintain confidentiality these hospitals will be 
referred to as site A and site B.  Site A is a large teaching hospital and site B is a smaller 
community hospital.  In 1997, these two separate organizations merged into this new 
health system.  Each of these medical institutions came into the merger with their own 
unique practices by the dietitians.  The health system may be considering standardizing 
practice across the hospitals.   
Outcomes research provides a practical approach to health care evaluation.  The 
three outcomes categories that are typically assessed in outcomes research are clinical, 
patients, and cost outcomes (Splett 1996).  Outcome data on nutrition intervention has 
been done in the areas of cardiovascular disease; hypertension; diabetes mellitus; obesity; 
surgical recovery; and nutrition for women, infants, and children (Gallagher-Allred, 
Voss, and Gussler 1995).  Outcomes research for cancer patients on TPN is not only 
needed to standardize dietetic practice for the institutions included in this study, but also 
to determine if patient outcomes are improved by dietitian involvement.   
 
Problem Statement 
 
 Screening and assessment of the cancer patient is the key to effective nutrition 
intervention and management (Bloch 1998).  Patients are classified as low, moderate, or 
high risk, and follow up on patients is to be completed in 7, 5, or 4 days, respectively.  
This study investigated if timely dietitian follow up correlated with the outcomes of 
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weight gain, improved protein status, decreased length of TPN administration, and 
decreased length of hospital stay of leukemia patients.  Timely dietitian follow up was 
defined as meeting the protocol of documentation every four days.  This study also 
compared dietetic practice across the two hospitals.  Dissemination of the outcome 
findings would provide a basis to standardize clinical practice and maximize the quality 
of care in each institution.    
 
Research Questions 
 
Ho1:  Timely follow up documentation from the dietitian will not significantly influence 
the outcome of length of hospital stay for patients in this sample.   
H1:  Timely follow up documentation from the dietitian will significantly decrease the 
length of hospital stay for patients in this sample.   
Ho2:  Timely follow up documentation from the dietitian will not significantly influence 
the outcome of length of TPN for patients in this sample.  
H2:  Timely follow up documentation from the dietitian will significantly decrease the 
duration of TPN for patients in this sample. 
Ho3:  Timely follow up documentation from the dietitian will not significantly influence 
the outcome of protein status for patients in this sample.  
H3:  Timely follow up documentation from the dietitian will significantly improve protein 
status for patients in this sample. 
Ho4:  Timely follow up documentation from the dietitian will not significantly influence 
the outcome of weight for patients in this sample.  
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H4:  Timely follow up chart notes from the dietitian will significantly increase weight 
gain for patients in this sample. 
Ho5:  Dietitian involvement with TPN protocols would not be significantly different 
between the two institutions.   
H5:  Dietitian involvement with TPN protocols would be significantly different between   
       the two institutions.   
 
Assumption of the Study 
 
 It was assumed in this study that the registered dietitian or dietetic technician had 
calculated accurate calorie and protein needs for each patient.  It was also assumed that 
the medical record was an accurate documentation of the care provided and contained all 
of the chart notes that were completed.   
 
Delimitation of the Study 
 
 The results of this study were only applied to 115 adult males and females who 
had acute lymphocytic leukemia, acute myelogenous leukemia, chronic lymphocytic 
leukemia, or chronic myelogenous leukemia and were admitted and discharged from one 
of the two hospitals during the time span of January 1, 1997 through December 31, 2000.   
 
Limitations of the Study 
 
 Due to having only two sites and one specific patient population, there was not a 
large variance of dietitians who would have been charting in the medical records. 
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Therefore, this sample may not represent the practices of all of the dietitians from the two 
facilities.  The lab values included in this study were recorded to the nearest day of admit 
and discharge, thus some of the lab values may be a few days off from the admit or 
discharge date.  The type and duration of chemotherapy or other medications were not 
recorded which could have a further impact on the patient’s health status during the 
course of the hospital stay.       
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 Review of the Literature 
Introduction 
 
With the increasing costs of health care, medical nutrition therapy must be 
justified to both payers and providers.  These changes are affecting the profession of 
dietetics more than ever as practitioners are experiencing the need to demonstrate that 
they can improve patient outcomes.  In today’s health care system, the response to this 
need is outcomes research (Gallagher-Allred, Voss, and Gussler 1995).    
There are three major factors that have motivated the outcomes research 
movement.  First, with so many attempts to reduce and contain health care costs, there is 
a concern that the quality of care will decline (Epstein 1990).  Quality of care is no longer 
measured by standards or by how or who is performing the task.  Insurers, administrators, 
and consumers are now the ones who are determining quality (Shiller and Moore 1999).  
Health care reimbursement is influenced by managed care organizations serving over 
50% of the United States population (August 1996a).  Outcomes can support the 
determination of the effect of cost containment on the quality of care (Epstein 1990).  
Second, with the competition in health care, purchasers want to know what they are 
getting for their money.  Outcomes can stipulate the quantity and quality of the goods 
being purchased.  Third, outcomes research can identify unexplained geographic 
differences in health care practices and how resources are used (Epstein 1990).   
Health care costs have escalated above 15% of the Gross National Product.  Some 
of the trends multiplying health care costs include increased accessibility of high-cost 
technologies, the aging population, individuals not having access to proper medical care, 
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and increased utilization of resources due to disease and trauma from violence.  Health 
care organizations are seeking cost-effective practices that will maintain the quality of 
care (Splett 1996).   
Outcomes research has been identified as a necessary future role for dietitians 
(Dahlke et al. 2000).  “Outcomes research is particularly relevant to nutrition support.  
Outcomes research may provide the methods by which the clinical effectiveness of 
nutrition support can be demonstrated and its monetary cost determined”  
(August 1995, 3, 4).     
 
What is Outcomes Research? 
 
Definition 
 Outcomes research is frequently defined as “the rigorous determination of what 
works in medical care and what does not” (August 1995, 2; Tanenbaum 1993, 1268). 
Outcomes research has been referred to as “the outcomes movement”, “the third 
revolution in medical care”, “a technology of patient experience”, and “a belief in the 
practical superiority of statistical knowledge to other types of knowledge” 
(August 1995, 1).  The American Society for Parenteral and Enteral Nutrition (ASPEN) 
defines an outcome as, “The measured result of the performance of a system or process” 
(ASPEN Board of Directors 1995, 2).  Splett identifies the driving question of outcomes 
research as “What works best, for whom, and at what cost?” (Splett 1996, 6).   To 
summarize, “Information on outcomes empowers” (August 1995, 1).    
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Objectives 
 “The purpose of outcomes research is to collect data to help patients, providers, 
payers, and administrators make informed choices regarding medical treatment options 
and health care policy” (August 1995, 2).  The goals of outcomes research include 
evaluating the effectiveness of current clinical practices; investigating the use of 
preventive, therapeutic, and rehabilitative procedures; thorough and timely evaluations; 
and dissemination of the findings for improvement of clinical practice (Splett 1996).  The 
overreaching goal of outcomes research is to maximize the quality of care and minimize 
the total costs (Gallagher-Allred, Voss, and Gussler 1995).   
 
Components of Outcomes Research 
 
Methodology 
The foundation of outcomes research is that poor outcomes detect poor quality of 
care. A leading researcher in methodologies of quality in health care, Avedis 
Donabedian, defines quality in health care as, “the extent to which care provided is 
expected to achieve the most favorable balance of risks and benefits” (Srp, et al. 1991, 
133).  Analyzing the factors that affect outcomes can improve health care procedures as 
well as outcomes.  Quality of care includes controllable and uncontrollable factors.  
Figure 1 identifies those factors, which can affect the quality of care and patient 
outcomes.   
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  In outcomes research, the goal is effectiveness and efficiency rather than efficacy.  
iveness identifies the outcomes that were achieved in ordinary practice settings, 
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while efficacy is associated with outcomes achieved in ideal settings or controlled 
experiments (Splett 1996 and Davies et al. 1994).  
Types of Outcomes 
 The three outcomes that are typically assessed in outcomes research are clinical 
outcomes, patient outcomes, and cost outcomes.  Clinicians are responsible for 
identifying what clinical outcomes are important in specific diseases.  Clinical outcomes 
define the results of the intervention (Splett 1996).  August (1996b) breaks down clinical 
outcomes into two categories of primary and secondary outcomes.   Primary outcome 
examples include those that are study specific, physiologic, and anatomic.  Examples of 
secondary outcomes include length of stay, readmissions, medication use, and rates of 
infection.  Successful clinical outcomes can be determined from a combination of expert 
judgment, previous studies, and established norms (Splett 1996).   
 Patient outcomes focus on consequences that would interest the patient.  Patient 
outcomes may include survival, side effects of treatment or disease, relief of symptoms, 
quality of life, and satisfaction with the care and cost received (Splett 1996).  Patient 
outcomes may be categorized into functional outcomes and patient satisfaction outcomes 
(August 1996b).  The project director for Indicator Development Outcomes Research at 
the Joint Commission on Accreditation of Healthcare Organizations (JCAHO) stated, 
“Patient outcomes are influenced by all activities of a health care organization” (Srp et al. 
1991, 132).   
 Cost outcomes describe the financial value of the resources utilized or saved as a 
result of the intervention.  Examples of cost outcomes include costs to treat side effects, 
costs of medications, and costs saved from shortened length of hospital stay.  Cost 
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outcomes may be reported in dollar amounts, a ratio of costs to clinical outcomes, or a 
ratio of costs to quality of life (Splett 1996).   
Benefit Analysis 
The three types of benefit analyses commonly used in outcomes research are risk 
benefit, cost benefit, and cost effectiveness analyses.  Risk-benefit analysis compares the 
morbidity, mortality, and reduced quality of life from a treatment to reduced morbidity, 
mortality, and increased quality of life resulting from the treatment.  Risk-benefit analysis 
is not monetary.  Cost-benefit analysis is a relation of the monetary costs to the monetary 
benefits of the intervention.  The problem with cost-benefit analysis is that precise costs 
are often impossible to determine.  Also, cost-benefit analysis may not be of interest to 
clinicians who work with human problems, which are difficult to place a price tag upon.  
Cost-effectiveness analysis is the cost of achieving a predetermined outcome.  In cost-
effectiveness analysis, clinicians and patients determine the desired outcomes to be 
measured.  The cost of achieving these outcomes is analyzed and the best intervention is 
the one that attains the desired outcomes at the lowest cost (August 1998).   
Consumers of Outcomes Data 
 There are several potential consumers of outcomes data.  Patients may be some of 
the main beneficiaries as quality of life can be improved through outcomes research 
(August 1998).  By knowing outcomes, patients may be able to participate in decisions 
about treatment alternatives (Splett 1996).  The use of unnecessary and ineffective 
treatments may be reduced (August 1996a).  The application of outcomes research will 
aid clinicians in determining best possible practice methods (Splett 1996).   
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Clinicians should be interested in outcomes data as healthcare is being 
economized and funding for specialty positions is decreasing (August 1998).  Outcomes 
research allows clinicians to demonstrate their productivity as well as their ability to 
improve outcomes and reduce costs (August 1996a).   
Healthcare organizations can use outcomes data to improve the way they do 
business (August 1998).  Outcomes data may be used by hospitals to establish guidelines 
and protocols for improved patient care, demonstrate regulatory compliance, identify 
areas for improvement, and to market their services (Gallagher-Allred, Voss, and Gussler 
1995).   
Outcomes data is also valuable to healthcare payers and purchasers, which 
includes insurance companies, Medicare, Medicaid, and managed care organizations 
(Splett 1996).  Payers and purchasers are interested in data on the effectiveness of care as 
the information may help them reduce healthcare costs, regulate care and make 
reimbursement decisions, make purchasing decisions and establish national guidelines 
(Gallagher-Allred, Voss, and Gussler 1995).     
The healthcare sector including providers, insurers, and government can utilize 
outcomes data and employ joint planning across the overarching health care system.  The 
most cost effective settings for specific care or diseases can be determined using 
outcomes data (Splett 1996).   
Steps have been made by the health care sector in the direction of outcomes 
research.  In the 1980’s, the American Dietetic Association (ADA) and the JCAHO 
pioneered Agenda for Change to move from process-oriented standards of care to 
outcome-oriented indicators of quality care (Merkens 1994).  The federal government has 
 12
funded and facilitated outcomes research.  In 1989, Congress established the federal 
Agency for Health Care Policy and Research, which is overtly committed to conducting 
outcomes research and disseminating the results (Tanenbaum 1993).   
 
What is Risk Adjustment? 
 
Definition 
 In outcomes research, the goal is to determine the association between treatment 
and outcomes.  The difficulty with this is that there are several other factors, which 
influence patient outcomes.  Adjusting for these other factors is called risk adjustment or 
sometimes referred to as “case-mix adjustment”.  Risk factors can directly influence a 
patient’s outcome.  The reliability of outcomes research may depend on adjusting for 
potential interfering risk factors.  There are several classes of risk factors that could be 
identified.  In risk adjustment, the main components are severity and comorbidity with 
demographic and psychosocial factors.  Severity of illness defines the extent or the 
effects a condition has on that person.  It usually reflects the patient’s primary diagnosis 
or disease.  Comorbidity describes the potential effects of other existing clinical 
problems.  Demographic and psychosocial factors may have an effect on the causes, 
treatment, or the outcomes (Kane 1997).  
Severity 
 The two terms used in adjusting for severity are severity of disease and severity of 
illness.  Severity of disease is often the severity and the importance of the principle 
diagnosis.  The severity of illness is all of the patient’s diagnoses combined to obtain a 
score describing the patient’s overall level of illness.  The severity of illness includes the 
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importance and severity of the principle diagnosis as well as the importance and severity 
of each secondary diagnoses.  Ideally the severity of illness should be collected prior to 
and after symptom onset, but before the intervention.  Severity of illness is important to 
incorporate into a research study as it adjusts for selection bias, improves the capacity to 
predict outcomes, and forms a basis for subgroup analysis.  If patients are not randomly 
distributed into groups, selection bias may occur.  Adjusting for the severity of illness 
will deal with possible confounding differences in initial severity, and reduce the 
possibility that the outcome is a result of the level of severity of the population studied.  
Measures of severity can be used to explain some of the variance in outcomes. Subgroups 
of patients with more or less disease severity may respond differently to the intervention.  
Subgroups may be selected for different analyses in the early stages of the study (Smith 
1997).   
 There are several measures that can adjust for severity of illness.  Some of the 
measures that have shown consistent reliability and validity include Acute Physiology, 
Age and Chronic Health Evaluation (APACHE), Computerized Severity Index (CSI), 
diagnoses-related groups (DRGs), Disease Staging (DS), and Medigroups.  All of these 
measures have been constructed for use on hospitalized patients (Smith 1997).   
Comorbidity 
 “Comorbidities, or the coexisting diagnoses, are diseases unrelated in etiology or 
causality to the principle diagnosis” (Nitz 1997, 154).  Comorbidity is the severity and 
importance of each secondary diagnosis.  Comorbidities do not include treatment 
complications or complications of the disease.  Comorbid conditions should be measured 
prior to any treatments.  Comorbidities are measured for similar reasons as the severity of 
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illness.  Comorbidities can help to remove observed variation in outcomes in different 
groups and help to isolate the effects of the treatment. Comorbidity is a useful measure to 
establish the patient’s usual state of health before treatment (Nitz 1997).      
    Several measures are available for adjusting for comorbidities.  Measures 
specific for ambulatory care settings include the Chronic Disease Score (CDS) and 
Ambulatory Care Groups (ACGs).  These measures were actually created to assess 
severity of illness, but have been adapted for comorbidities by excluding the disease of 
primary interest when calculating the scores (Nitz 1997). 
The measures developed for use in a hospital setting include Comorbidity Index 
(CI), Duke Severity of Illness Checklist, Kaplan and Feinstein, and the Charlson 
Comorbidity Index (Nitz 1997). The Charlson Comorbidity index classifies comorbidities 
in an ordinal scale according to their prognosis.  It was first developed based on a cohort 
study of over 600 patients admitted to an acute care hospital.  The index was then 
validated in another cohort study of breast cancer patients (Charlson et al. 1987).  In 
1992, Deyo and colleagues adapted the Charlson Comorbidity Index for use with the 
International Classification of Diseases, 9th edition, Clinical Manifestations (ICD-9-CM) 
codes in a study of outcomes of lumbar spine surgery.  The conclusion they reached was 
that “the Charlson index can be valuable when used with the ICD-9-CM administrative 
databases” (Deyo, Cherkin, and Ciol 1992, 619).  The Charlson Comorbidity Index and 
the adapted comorbidity index with the ICD-9-CM codes are listed in appendices A and 
B, respectively.   
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Demographic and Psychosocial Factors 
 “Demographic, psychological, and social variables may be risk factors for an 
illness or other outcomes, confounders of results, or modifiers of treatment effect” 
(Derose 1997, 175).  These variables may even be viewed as outcomes themselves.  Any 
variables that could impact the outcomes or define the population being studied are the 
variables of interest.  Traditional variables commonly measured include age, sex, ethnic 
background, race, religion, socioeconomic status, occupation, and martial status. 
Psychological and social variables are often more complicated to measure because they 
are abstract concepts and need to be fit into a measurement scale.  There are many 
measurement scales in the literature.  Scales may measure different dimensions of these 
variables, but must be applicable to the population being studied, the setting, and the 
expected range of responses. Categories of some of the scales include depression scales; 
anxiety scales; psychological well-being scales; social health scales; and health beliefs, 
attitudes, and behavior scales (Derose 1997).   
 
Parenteral Nutrition 
 
Definition 
“Parenteral nutrition (PN) is the intravenous provision of macronutrients and 
micronutrients to the individual who has a nonfunctional gastrointestinal tract, has an 
enteral tract that cannot be accessed, or is unable to digest nutrients” (McCrae 1997, 
181).  “TPN [total parenteral nutrition] permits a highly concentrated, hypertonic solution 
to be administered to the patient” (McCrae 1997, 181).  Parenteral nutrition provides 
protein in the form of amino acids, carbohydrate in the form of dextrose, and fat, 
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vitamins, and minerals (Matarese and Steiger 1999).  Parenteral nutrition or intravenous 
feeding has several different names.  TPN and hyperalimentation are the two most 
common names.  Other specific terms include central parenteral nutrition (CPN), central 
venous alimentation (CVA), peripheral parenteral nutrition (PPN), and peripheral venous 
alimentation (PVA) (Heimburger and Weinsier 1997).   The route of administration 
depends on the length of therapy, the goal of nutrition therapy, availability of intravenous 
(IV) access, severity of illness, and fluid status (Matarese and Steiger 1999).   
Administration 
The expected duration of therapy, the patient’s nutritional status, and venous 
presentation are the main determinants for the route of administration for parenteral 
nutrition.  Parenteral nutrition through a peripheral vein is generally for patients who 
require therapy for less than 14 days, do not have severe malnutrition, and have good 
peripheral access. With peripheral TPN it is difficult to provide the full nutritional 
requirements because of the limits with the osmolarity of the solution to prevent 
thrombophlebitis (inflammation of a vein) (DeChicco and Matarese 1998).  
Central TPN is recommended for patients who require long-term therapy, have a 
fluid restriction, or have high metabolic requirements.   Since the solution is infused into 
a large vein, there are no osmolarity limits.  The subclavian vein is the preferred site for 
central TPN. The internal or external jugular vein or femoral vein can also be used 
(DeChicco and Matarese 1998).  It is recommended that TPN not be discontinued until at 
least 50% of the patient’s nutrient needs and 100% of the patient’s fluid needs have been 
met through oral or enteral feeding for three consecutive days (Winkler and Lysen 1993).   
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The duration and the type of therapy will determine the access device.  A 
percutaneous venous catheter is temporary and is usually only used for hospitalized 
patients.  A permanent catheter is placed surgically and is used for long-term therapy. 
Broviac, Hickman, and Groshong are examples of permanent catheters.  A peripherally 
inserted central catheter (PICC) is an alternative for central access for TPN.  PICC lines 
were often used for long-term antibiotic therapy, but TPN has been infused with good 
results (DeChicco and Matarese 1998). 
Macronutrients 
 Parenteral nutrition formulas contain protein, carbohydrate, and fat.  These 
nutrients are delivered in ratios, which are tailored to meet the needs of each individual 
patient (Skipper 1998).    
Protein 
 In parenteral nutrition, the main function of protein is to maintain nitrogen 
balance and prevent skeletal muscle breakdown or gluconeogenesis.  The protein 
requirement for healthy adults is 0.8 g/kg per day.  For critical illness, the 
recommendations vary slightly.  A range of 1.2 to 2.0 g/kg per day of protein is 
recommended for most patients (Skipper 1998).  Amino acids contain 4 calories per gram 
(McCrae 1997).  Commercial amino acids exist in concentrations of 3.5, 5.5, 7, 7.5, 8.5 
10, 11, and 15%.  Peripheral administration will most often utilize the dilute 
concentrations (3.5% and 5.5%).  Central TPN administration most often uses the 
concentrated amino acid solutions (8.5, 10, 11, and 15%).   Essential amino acid 
proportions in the parenteral solutions are based upon the Food and Agricultural 
Organization and the World Health Organization recommendations (Skipper 1998).   
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Carbohydrate 
 Carbohydrate is the primary energy source in the parenteral solution.  The 
requirement for carbohydrate has not been clearly defined.  A minimum amount of 100 g 
per day is most frequently used. This minimum amount is based on research, which 
demonstrated that two liters of fluid with 50 g of carbohydrate per liter suppresses 
gluconeogenesis and consequently protein catabolism. The recommendation for critically 
ill patients, is that carbohydrate intake be reduced to 4 mg/kg per minute.  Carbohydrate 
solutions contain 3.4 calories per gram of dextrose.  Commercial carbohydrate is 
composed of anhydrous dextrose monohydrate in sterile water.  Carbohydrate solutions 
are available in concentrations of 5% to 70% (Skipper 1998).   
Lipids 
 Lipids are included in the parenteral solution as a source of essential fatty acids 
and calories.  Requirements for lipids can be met with 4% of calories as linoleic acid or 
about 10% of calories from a commercial lipid emulsion from safflower oil (Skipper 
1998).  To prevent a deficiency, approximately 4% of calories must be provided as 
essential fatty acids (McCrae 1997).  Research has validated the recommendation to limit 
lipids to 1 g/kg per day or 25% to 30% of total calories.  These limits have stemmed from 
research that long-chain fatty acids can impair neutrophil function, endotoxin clearance, 
and complement synthesis.  Commercial lipids are aqueous emulsions of safflower or 
soybean oil, consisting primarily of long chain triglycerides.  The three concentrations 
available commercially are 10%, 20%, and 30%.  As well as the fatty acids, lipids also 
contain glycerol emulsifiers, which increase the calories to 1.1 calories per mL for a 10% 
emulsion and 2.0 calories per mL for a 20% emulsion (Skipper 1998).  
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Additives 
Electrolytes 
 
 Electrolyte requirements vary for each patient depending on body weight, any 
malnutrition or catabolism, amount of electrolyte depletion, organ function, electrolyte 
losses, and the disease process.  Medications may also have an effect on electrolyte 
requirements.  There are several different recommendations for parenteral electrolytes.  
Skipper (1998) summarized and compared three investigator’s electrolyte 
recommendations (Table 1).  The recommendations need to be utilized along with 
clinical judgment of the practitioner.   
Table 1.  Parenteral Electrolyte Recommendations 
      Investigators                                   
    Sheldon   Grant    Schlictig 
 
Potassium 120-160 mmol/d  70-150 mEq   70-100 mEq 
Sodium 125-150 mmol/d  60-150 mEq   70-100 mEq 
Phosphorus 12-25 mmol/1000 kcal 7-10 mmol/1000 kcal  20-30 mmol 
Magnesium 7.5-10 mmol/d  0.35-0.45 mEq/kg/d  15-20 mEq 
Calcium     0.2-0.3 mEq/kg/d  10-20 mmol 
Chloride     Equal to Na to prevent 
      Acid-base disturbances   
Source:  Skipper A, 1998.  Principles of Parenteral Nutrition.  In Contemporary Nutrition Support 
Practice A Clinical Guide, ed. Laura Matarese and Michele Gottschlich, 227-242.  Philadelphia, 
PA: W.B. Saunders Company.   
 
Vitamins 
 Vitamins and minerals proved to be a requirement in TPN solutions early in 
history.  Vitamin free parenteral solutions resulted in deficiency states that were not often 
seen in patients who consumed a normal diet.  The American Medical Association 
(AMA) has issued the current vitamin recommendations for TPN, which have remained 
unchanged since 1975.  Table 2 delineates these recommendations. Commercial 
preparations are available that follow the AMA recommendations.   Vitamin K is not 
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included in commercial products as many patients are on anticoagulants.  Vitamin K may 
be added to the TPN with a dose of 10 mg per week or 1 mg daily (Skipper 1998).   
Table 2.  AMA Recommendations for Parenteral Vitamin Intake 
Vitamin  Amount per day  
 
Vitamin A  3,300 IU 
Vitamin D     200 IU 
Vitamin E      10 IU 
Ascorbic Acid    100 mg 
Folacin    400 µg 
Niacin        40 mg 
Riboflavin        3.6 mg 
Thiamine         3 mg 
B6 (pyridoxine)       4 mg 
B12 (cyanocobalamin)       5 µg 
Pantothenic acid     15 mg 
Biotin       60 µg      
Source:  Nutrition Advisory Group of the Department of Foods and Nutrition, American Medical 
Association. 1979. Multivitamin Preparations for Parenteral Use: A Statement by the Nutrition 
Advisory Group.  Journal of Parenteral and Enteral Nutrition 3: 258-262.   
 
Minerals 
 In 1977, the AMA also developed the recommendations for trace minerals in the 
parenteral solution.  Table 3 presents these recommendations.  There are several 
commercial preparations available and in different concentrations.  Zinc, copper, 
chromium, and manganese are available with or without the addition of selenium and 
iodide (Skipper 1998).     
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Table 3.  AMA Recommendations for Parenteral Mineral Intake 
Mineral  Amount per day      
 
Zinc   2.5-4.0  mg 
   (2.0 mg/day in acute catabolism, 
   12.2 mg/L of small bowel fluid losses, 
   17.1 mg/kg of stool or ileostomy output) 
Copper  0.5-1.5 mg 
Chromium            10.0-15.0 µg  
Manganese  0.15-0.8 mg 
Selenium           20.0-40.0 µg    
 
Source:  American Medical Association Department of Foods and Nutrition.  1979.  Guidelines 
for essential trace element preparations for parenteral use.  A statement by an expert panel.    
Journal of the American Medical Association, 24:2051.   
 
 
 
Insulin 
 Hyperglycemia is commonly seen in patients receiving TPN.  Insulin may be 
added to the solution to regulate blood glucose levels.  It has been documented that the 
insulin absorbs to glass bottles, polyvinyl chloride bags, and tubing used for the TPN 
administration.  The only insulin loss will usually occur within the first hour.  The 
addition of insulin can result in good control of blood glucose levels (Skipper 1998).   
Indications 
 “Parenteral nutrition was originally developed to nourish those whose 
gastrointestinal tract was not capable of digesting and absorbing nutrients.  The ultimate 
indication for parenteral nutrition continues to be a nonfunctioning gastrointestinal tract 
and documented inability to tolerate enteral feeding” (Skipper 1998, 227).  The patient 
should also be at nutritional risk.  Nutritional risk is defined as a weight loss of at least 
10% of preillness weight and a patient who has not had anything by mouth for 5 to 7 
days.  TPN is only indicated if the administration would be long-term (more than 2 
weeks) (Skipper 1998; ASPEN 1993).  The American Society for Parenteral and Enteral 
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Nutrition (ASPEN) has published Practice Guidelines for Parenteral Nutrition (Appendix 
C).  The first practice guideline states “Patients who are candidates for parenteral 
nutrition support cannot, should not, or will not eat adequately to maintain their nutrient 
stores.  These patients are already or have the potential of becoming malnourished” 
(ASPEN 1993, 10SA).     
There are several guidelines that have been developed by organizations for the 
selection of patients to receive TPN.  In 1989, the American Gastroenterology 
Association (AGA) published guidelines for parenteral nutrition.  Categories of 
indications for TPN from AGA include short bowel syndrome, inflammatory bowel 
syndrome, chronic intestinal disorders, gastrointestinal fistulas, postoperative 
complications, preoperative preparation, pancreatitis, cancer, neurologic and pulmonary 
disease, and neonates and infants (Sitzmann, Pitt, and The Patient Care Committee of The 
American Gastroenterological Association 1989).  In 1990, the U.S. Department of 
Health and Human Services funded a technology assessment and practice guidelines 
forum.  Categories of these guidelines for selection of patients to receive TPN include 
those with malignant disease (cancer), perioperative total parenteral nutrition, 
inflammatory bowel disease, short-bowel syndrome, hepatic disease, pancreatitis, critical 
care, renal failure, Acquired Immunodeficiency Syndrome, respiratory failure, and eating 
disorders.  In 1986, ASPEN published the first of these guidelines, and they were revised 
and expanded in 1993 (Skipper 1998).  The latest revision was published in 2002 
(ASPEN 2002).  
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Malnutrition 
ASPEN defines malnutrition as, “Depletion of an essential nutrient or tissue 
compartment”(ASPEN 1993, 5SA).  Clinically malnutrition is diagnosed if the serum 
albumin level is less than 3.5 g/dL, total lymphocyte count is less than 1,800 mm3, or if 
there is an unplanned decrease in body weight by 15% (Gallagher-Allred et al. 1996).  A 
weight loss greater than 10% is often associated with functional abnormalities and a poor 
clinical outcome.  With malnutrition other complications are more likely to occur 
including weakness, compromised immunity, and decreased wound healing.  In 
hospitalized patients, there may be as many as 50% that are moderately malnourished and 
5% to 10% of patients may be severely malnourished (ASPEN 1993).  Hospital charges 
for malnourished patients may range from 35% to 75% higher than well-nourished 
patients (Gallagher-Allred et al. 1996).  In 1993, ASPEN developed Practice Guidelines 
for Malnutrition, which can be found in Appendix D.    
The ASPEN Guidelines state that enteral tube feeding should be considered if a 
patient could not maintain adequate oral intake.  If enteral support is not enough, both 
enteral and parenteral support may be initiated.  Parenteral nutrition alone may be 
initiated if enteral nutrition is not meeting nutrient requirements or if enteral feeding is 
contraindicated (ASPEN 1993). 
Cancer 
“Cancer patients frequently become malnourished during the course of their 
disease because of the malignancy’s direct effects or as a result of treatment side effects” 
(ASPEN 1993, 12SA).  In cancer patients with malnutrition, nutrition support may 
improve nutrition indices and overall patient performance status.    
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The AGA guidelines for cancer state, “parenteral nutrition may be indicated in the 
cancer patient if anticipated treatment regimens are likely to aggravate or induce 
nutritional compromise” (Sitzmann, Pitt, and The Patient Care Committee of The 
American Gastroenterological Association 1989).   
ADA developed clinical indicators for nutrition support in oncology as part of 
their Agenda for Change to be used by organizations with membership to the JCAHO.  
The indicators developed for oncology are as follows:  
No patient is on a clear liquid diet or nothing by mouth without nutrition support 
for more than five days; All patients at moderate or high risk are identified by 
screening and assessed within 72 hours of admission; Patients at moderate or high 
risk are able to implement nutrition care plan at discharge (Queen, Caldwell, and 
Balogun 1993, 342).     
The ASPEN Practice Guidelines do state however that nutrition support should 
not be routinely utilized for well-nourished or mildly malnourished cancer patients.  TPN 
may not benefit cancer patients who are unresponsive to chemotherapy or radiation 
therapy (ASPEN 1993; Sitzmann, Pitt, and The Patient Care Committee of The American 
Gastroenterological Association 1989).  Appendix E delineates the ASPEN Practice 
Guidelines for cancer.   
 
Leukemia 
 
Physiology 
 Leukemia is a cancer of the blood, specifically the white blood cells or 
lymphocytes.  Leukemia starts in the bone marrow and then can spread to the blood, 
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lymph nodes, spleen, liver, central nervous system, and other organs.  In leukemia there 
are too many abnormal white blood cells being produced, which inundate the bone 
marrow (Leukemia Society of America 1999a, b, c and The Leukemia and Lymphoma 
Society 2000).   
Organs of the immune system may be referred to as lymphoid organs as they are 
involved with the growth, development, and deployment of lymphocytes.  Lymphoid 
organs include the bone marrow, thymus, lymph nodes, spleen, tonsils and adenoids, 
appendix, and lymph tissue found in the small intestine called Peyer’s patches.  There are 
about one trillion white blood cells (Schindler 1993).  White blood cells include the 
neutrophils, monocytes, eosinophils, basophils, and lymphocytes.  Neutrophils and 
monocytes are phagocytes and can ingest and kill bacteria or fungi.  White blood cells 
help cure an infection by actually leaving the blood and invading the tissue to kill the 
bacteria or fungi that is causing an infection.  Eosinophils and basophils participate in 
allergic responses.  The three types of lymphocytes are T cells, B cells, and natural killer 
cells (Leukemia Society of America 1999a, b, c; The Leukemia and Lymphoma Society 
2000).  The B cells secret antibodies into the body’s fluids.  Each B cell produces one 
specific antibody.  B cells need the T cells in order to make antibodies against most 
substances.  T cells interact directly with their targets.  Natural killer cells are filled with 
potent chemicals and can protect against a wide variety of infections (Schindler 1993).   
 The bone marrow is the central cavity of the bone in which blood cell 
development takes place.  In adults bone marrow that is actively making blood cells is 
found only in the vertebrae, hip and shoulder bones, ribs, breastbone, and skull.  
Hematopoiesis is the process of making blood cells.  Stem cells make the blood cells in 
 26
the marrow.  Differentiation is the process of stem cells changing into the specific blood 
cells (Leukemia Society of America 1999a, b, c; The Leukemia and Lymphoma Society 
2000).  Figure 2 diagrams the differentiation process.   
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 Types of Leukemia 
The two main types of leukemia are lymphocytic and myelogenous.   Both of 
these types have both an acute and chronic form.   Lymphocytic and myelogenous 
indicate the cell type involved.  Lymphocytic leukemia develops from the lymphocytes in 
the bone marrow.  Myelogenous leukemia develops from granulocytes or monocytes, two 
types of white blood cells.  The four major types of leukemia are acute myelogenous 
leukemia (AML), acute lymphocytic leukemia (ALL), chronic myelogenous leukemia 
(CML), and chronic lymphocytic leukemia (CLL).  Acute leukemia is a disease that 
affects cells that are unformed or not yet fully developed.  The cells are growing so 
rapidly that they are not able to mature properly.  Immature cells cannot carry out their 
normal functions.  The immature cells, lymphoblasts or myeloblasts, reproduce in an 
uncontrolled way and crowd out the cells that make normal blood cells.  Acute leukemia 
is rapidly progressing, whereas chronic leukemia progresses more slowly.  Greater 
numbers of cells are developed; however they are not completely normal.  In chronic 
leukemia, some of these mature cells can perform their normal functions (The Leukemia 
and Lymphoma Society 2000).   
Acute Myelogenous Leukemia 
 AML, also called acute nonlymphocytic leukemia (ANLL), comprises about 40% 
of all leukemias in the Western world (Rohatiner and Lister 1996).   AML occurs in 
adults and children.  In adults, AML accounts for 80% of the acute leukemias. AML is 
more common in males (Lichtman 1995a).  AML results from acquired, not inherited, 
genetic damage to the DNA of developing cells in the bone marrow.  This results in 
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uncontrolled and increased growth of leukemic blasts that cannot function normally.  
Also there is a barrier to the production of normal cells, which leads to a deficiency of red 
blood cells (anemia), platelets (thrombocytopenia), and normal white blood cells, 
especially neutrophils (Leukemia Society of America 1999a).  Granulocytic sarcoma or 
chloroma are solid tumors.  It is very rare if tumor cells appear as a solid tumor (National 
Cancer Institute 2000a).   
 Environmental factors including, high-dose radiation exposure, chronic benzene 
exposure, and alkalizing agents may cause AML.  Among electrical workers, a small but 
significant increase in AML was found.  There are predisposing diseases to AML 
including AIDS, Down syndrome, Fanconi anemia, or Bloom syndrome (Lichtman 
1995a).  
 AML is difficult to initially detect.  The early signs of AML are similar to the flu 
or other common illnesses.  These symptoms may include fever, weakness, tiredness, or 
achiness in the bones or joints.  Blood tests are taken to count the number of each of the 
different types of cells.  If the results are not normal, a bone marrow biopsy is done.   
This identifies the type of leukemia present (National Cancer Institute 2000a).   
Staging 
 There is really no formal staging for AML.  Treatment choices depend upon 
whether the patient has already been treated.  These periods are referred to as untreated, 
in remission, or recurrent/refractory. Untreated AML is newly diagnosed leukemia with 
no prior treatment.  Features of untreated AML include 30% or more blasts in the bone 
marrow, abnormal white cell count and differential, abnormal hematocrit and 
hemoglobin, abnormal platelet count, and signs and symptoms of AML.  Remission is 
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identified by normal peripheral blood cell count, less than 5% of blasts in the bone 
marrow, and no signs of symptoms of AML.  Recurrent AML indicates the leukemia has 
come back after remission.  Refractory AML refers to the leukemia not going into 
remission after treatment (National Cancer Institute 2000b).   
Treatment 
 Successful treatment requires control of the bone marrow.  Specific treatment of 
the central nervous system (CNS) disease if present is also required.  However, only 5% 
of patients with AML develop CNS disease (National Cancer Institute 2000b).  There are 
two phases of treatment, induction (to attain remission) and post remission (to maintain 
remission).  Chemotherapy is the primary treatment for AML.  Radiation is utilized in 
certain cases.  Untreated AML will most often be treated with systemic chemotherapy.  
Intrathecal chemotherapy (injected directly into the spinal cord) will be used if leukemia 
cells are found in the brain.  Systemic chemotherapy is commonly used for AML in 
remission.  Radiation is given in recurrent AML to reduce symptoms (National Cancer 
Institute 2000a, b).   
In patients younger than 60 years of age during first remission, allogeneic or 
autologous bone marrow transplantation (BMT) may be considered.  Most studies 
express that relapses are decreased in the first remission after allogeneic BMT compared 
with chemotherapy alone.  However, similar survival rates are demonstrated due to graft-
versus-host disease and interstitial pneumonia with bone marrow transplants.  Between 
35% and 50% of AML patients in remission with autologous BMT survive disease free 
(National Cancer Institute 2000b).   
 30
In adult AML remission rates are adversely related to age.  The expected 
remission rate is greater than 65% for AML patients younger than 60 year of age.   
Remission status after induction therapy can be reached by about 60% to 70% of adults.  
More than 15% can survive 3 or more years and may be cured (National Cancer Institute 
2000b).   
Acute Lymphocytic Leukemia 
 ALL is most often thought of as a disease of childhood.  ALL accounts for only 
about 15% of adult acute leukemias (Hoelzer 1996).  ALL occurs most often in children 
age 10 and under, but then increases in frequency in older individuals.  ALL is very 
similar to AML in that there is an acquired genetic injury to the DNA of cells in the bone 
marrow.  Also the effects are the same as there is an increased growth and accumulation 
of lymphoblasts and the production of normal marrow cells are blocked (The Leukemia 
and Lymphoma Society 2000).   
 There are very few factors that have been associated with a risk of developing 
ALL.  High exposure to irradiation is one of the factors.  ALL has been found to occur at 
different rates in different locations.  More developed countries and higher 
socioeconomic groups are found to have a higher incidence of ALL.  There have not been 
any solid conclusions relating life-style factors and environmental factors with AML 
(The Leukemia and Lymphoma Society 2000).   
 ALL as with AML is difficult to identify, as the symptoms are very common.  
Patients may feel more tired easily, short of breath when physically active, pale 
complexion, petechiae, fever, discomfort in the bone and joints, and the lymph nodes 
may be enlarged from the accumulation of lymphoblasts.  Headaches or vomiting may 
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occur if leukemic cells are in the lining of the brain or spinal cord (The Leukemia and 
Lymphoma Society 2000).   Blood tests and a bone marrow biopsy are done to diagnose 
ALL.  A spinal tap may also be done (National Cancer Institute 2000c). 
Staging 
 There is no true staging for ALL.  As with AML, treatment depends on whether 
the patient has been treated before.  The same three periods of untreated, remission, and 
recurrent/refractory exist for ALL.  These periods have the same meaning for both ALL 
and AML (National Cancer Society 2000c).   
Treatment 
 The choice of treatment with ALL depends on the type of disease, the patient’s 
age, and overall condition.  Research has found prognosis to be better in patients younger 
than 35 years of age.  This is partly because there is an increased incidence of the 
Philadelphia (Ph) -chromosome in older adults with ALL.  Patients with the Ph-
chromosome are associated with a poorer prognosis and are rarely cured with 
chemotherapy (National Cancer Institute 2000d).  The Ph-chromosome was first 
identified as a short chromosome 22, but is actually a balanced translocation between 
chromosomes 9 and 22 (Cortes, Talpaz, and Kantarjian 1996).   
Chemotherapy is the primary treatment of ALL.  Treatment of ALL has two 
stages similar to AML, which are induction therapy (to attain remission) and continuation 
therapy (to maintain remission).  Chemotherapy may be administered for several years to 
maintain remission.  Systemic and intrathecal chemotherapy will be the main treatment 
for untreated ALL.  Chemotherapy, autologous or allogeneic BMT, or radiation may all 
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be utilized with ALL in remission.  Radiation and BMT may be used in recurrent ALL 
(National Cancer Institute 2000c).   
 For adults with ALL, 60% to 80% can attain remission status after induction 
therapy.  Aggressive post-remission chemotherapy demonstrates a long-term disease-free 
survival rate of approximately 40%.  Allogeneic BMT results in the lowest incidence of 
leukemia relapse (National Cancer Institute 2000d).    
Chronic Myelogenous Leukemia 
 CML accounts for about 20% of all cases of leukemia.  CML affects mostly 
adults and is more common among men than women (Lichtman 1995b).  CML accounts 
for approximately 7% to 15% of all leukemias in adults (Cortes, Talpaz, and Kantarjian 
1996).  The largest numbers of cases of CML are found in individuals aged 60 to 70 
(Barnett and Eaves 1996). CML results from an acquired injury to the DNA.  This change 
is not present at birth and it is not understood what produces this change.  CML allows 
for the development of white blood cells that can function normally.  This is an important 
difference from the acute leukemias and can explain why there is less severity in the early 
course of CML (Leukemia Society of American 1999b).  However, CML has a high 
potential to evolve rapidly into an accelerated fatal phase that is similar to acute leukemia 
(Lichtman 1995b).   
 There is not enough evidence to link genetic factors to CML.  High doses of 
irradiation are associated with a higher incidence of CML, as seen with the survivors of 
Nagasaki and Hiroshima.  Therapeutic radiation for other cancers has also been  
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correlated with an increased risk for CML (Cortes, Talpaz, and Kantarjian 1996; 
Lichtman 1995b; Barnett and Eaves 1996).  Almost all CML patients (90 to 95%) have 
the Ph-chromosome (Cortes, Talpaz, and Kantarjian 1996).   
 Common symptoms for the onset of CML include easily fatigued, shortness of 
breath when physically active, pallor, and discomfort from an enlarged spleen.  Blood 
and marrow cells both generally need to be examined to diagnose CML.  The white blood 
cell count will be high.  Of the white blood cells, a small proportion will be very 
immature and a larger proportion will be myelocytes and neutrophils (matured cells).  A 
cytogenetic analysis is also conducted to measure the number and normality of 
chromosomes.  Polymerase chain reaction increases the amounts of DNA and RNA to 
make them more detectable and assess the type of DNA and RNA.  Almost all CML 
patients are diagnosed in the first or chronic phase of the disease (Leukemia Society of 
America 1999b).   
Staging 
 CML progresses through different phases.  The chronic phase shows no 
symptoms of leukemia and few blast cells in the marrow and blood.  Less than 5% blasts 
and promyelocytes are in the peripheral blood and bone marrow (National Cancer 
Institute 2000f).  This phase may last for several months to several years (National 
Cancer Institute 2000e), with a median duration of 3.5 to 5 years (Cortes, Talpaz, and 
Kantarjian 1996).  In the accelerated phase, there are more blast cells in the blood and 
marrow and fewer normal cells (National Cancer Institute 2000e).  This phase is 
identified as greater than 5% blasts in either the peripheral blood or marrow, but less than 
30% in the peripheral blood and bone marrow (National Cancer Institute 2000f).  At least 
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20% of CML patients will not go through an accelerated phase and progress directly to a 
blastic phase (Cortes, Talpaz, and Kantarjian 1996).  During the blastic phase or “blast 
crisis”, more than 30% of the cells are blast cells.  The blast cells may form tumors in the 
lymph nodes or the bones (National Cancer Institute 2000e).  The transition between 
these three phases may occur gradually over a year or more.  The annual rate of 
progression from chronic to blastic is 5% to 10% in the first two years and 20% in the 
years following (National Cancer Institute 2000f).  There is also a refractory phase, 
during which leukemia cells do not decrease even when treatment is given (National 
Cancer Institute 2000e). 
Treatment 
        “CML is not curable with conventional chemotherapy or immunotherapy.  
Allogeneic bone marrow transplantation from related or unrelated donors is the only 
known curative therapy” (National Cancer Institute 2000f, 1).  However treatment may 
still include chemotherapy, radiation therapy, or BMT (National Cancer Institute 2000e).  
Patients age 60 and over have a worse prognosis. With allogeneic BMT, long-term 
survival rates of 50% to 80% and disease free survival rates of 30% to 70% may occur in 
the chronic phase.  BMT results are improved for patients in the chronic versus the 
accelerated or blastic phases, which have long-term survival rates of 15% to 40% and less 
than 15%, respectively.  Patients in the blast phase do not have a good response to any 
therapy (Cortes, Talpaz, and Kantarjian 1996).   
Chronic Lymphocytic Leukemia 
 Twenty-five to 30% of all cases of leukemia in the United States are CLL.  CLL 
is uncommon in patients younger than 30 years of age, but increases exponentially with 
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age for both men and women.  Men have higher incidence rates than women (Keating 
1996).  CLL is the most common adult leukemia (Kipps 1995).  According to studies in 
Olmstead County, Minnesota, the incidence of CLL has been increasing over the last 50 
years (Keating 1996). 
 In CLL, as with the other three types of leukemia, there is an abnormal 
uncontrolled growth of lymphocytic cells in the marrow resulting in an increase in 
lymphocytes in the blood.  In CLL as well as CML normal cells can be produced and 
function normally, which may account for less severity in the early course of the disease 
(Leukemia Society of America 1999c). 
 As with the other types of leukemia, the cause of CLL is unknown.  There is an 
association between exposure to benzene as rubber workers and petroleum workers 
present with CLL.  There is however, no association with exposure to ionizing radiation 
with CLL (Keating 1996).  Genetics are involved as first-degree relatives have a threefold 
greater likelihood of getting the disease than other people (Leukemia Society of America 
1999c).   
 The symptoms of CLL develop gradually.  Tiredness, shortness of breath when 
physically active, weight loss, and sometimes recurrent infections of the skin, lungs, 
kidneys or other sites are symptoms of CLL.  Diagnosis includes examining blood and 
marrow cells.  The white cell count will be increased, but platelets and red cell counts 
may be decreased.  Immunoglobulins in the blood may also be deficient.  A cytogenetic 
analysis is done to determine abnormality of chromosomes (Leukemia Society of 
America 1999c).   
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Staging 
 Staging is used to predict prognosis, determine treatment, and treatment results.  
There is not a standard staging system for CLL.   The Rai staging system and Binet 
classification system are delineated below according to the National Cancer Institute’s 
Physicians Desk Query (2000g).     
Rai Staging System 
Stage 0 – Absolute lymphocytosis (>15,000 per cubic millimeter) 
without adenopathy, hepatosplenomegaly, anemia, or 
thrombocytopenia.   
Stage I – Absolute lymphocytosis with lymphadenopathy without 
hepatosplenomegaly, anemia, or thrombocytopenia.  
Stage II – Absolute lymphocytosis with either hepatomegaly or 
splenomegaly, with out without lymphadenopathy 
Stage III – Absolute lymphocytosis and anemia (hemoglobin <11 
g/dL) with or without lymphadenopathy, hepatomegaly, or 
splenomegaly. 
Stage IV – Absolute lymphocytosis and thrombocytopenia (<100,000 
per cubic millimeter) with or without lymphadenopathy, 
hepatomegaly, or anemia 
 
Binet classification 
Clinical stage A – No anemia, thrombocytopenia and fewer than three 
areas of lymphoid involvement (Rai stages 0, I, and II)* 
Clinical stage B – No anemia or thrombocytopenia with three or more 
areas of lymphoid involvement (Rai stages I and II)* 
Clinical stage C – Anemia and/or thrombocytopenia regardless of the 
number of areas of lymphoid enlargement (Rai stages III and IV) 
*Lymphoid areas include cervical, axillary, inguinal, and spleen 
 
  The most common staging system used in the United States is the Rai staging 
system and Binet staging is the most common system in Europe.  There is also a staging 
system called total tumor mass score; however, this system has not received wide 
acceptance (Keating 1996).  The International Workshop on Chronic Lymphocytic 
Leukemia recommended an integrated Binet/Rai system as follows: A(0), A(I), A(II); 
B(I), B(II); and C(III), C(IV) (Keating 1996; National Cancer Institute 2000g).  This 
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staging system however is not widely used.    Patient survival may range from less than 
one year after diagnosis to 20 years of excellent health after diagnosis (Keating 1996). 
Treatment 
 With CLL, a more conservative approach is taken with treatment because CLL is 
usually not curable, progresses slowly, and most frequently occurs in the elderly 
(National Cancer Institute 2000g).  Patients who have minimal changes in their blood and 
few related infections are generally not treated.  Signs of progression of CLL include 
rapid increase of lymphocyte counts in the blood, enlarged lymph nodes, enlarged spleen, 
worsening anemia, and decreasing platelet count.  Chemotherapy is the most commonly 
used treatment when the disease has progressed.  Radiation may be used to shrink lymph 
node masses.  BMT may be utilized, but is more successful in younger patients 
(Leukemia Society of America 1999c).  Leukapheresis may be used to take out extra 
lymphocytes (National Cancer Institute 2000f).   
Side Effects of Treatment 
Chemotherapy 
Therapeutic measures are necessary in most cases of cancer to control, eradicate, 
or minimize the neoplastic process.  Symptoms of chemotherapy side effects may occur 
within hours of administration or several days later (Bloch 1998).  Chemotherapy affects 
tissues that require a high rate of cell division, which include the lining of the mouth, the 
lining of the intestines, the skin, and the hair follicles.  This is why mouth ulcers, 
diarrhea, and hair loss are so common after chemotherapy (The Leukemia and 
Lymphoma society 2000).  After chemotherapy begins, anorexia may develop.  
Chemotherapy drugs may cause xerostomia (dry mouth), dysgeusia (a change in the taste 
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of food), and odynophagia (pain upon swallowing).  Nausea and vomiting is a side effect 
of chemotherapy, which can result in decreased calorie intake, weight loss, cachexia, 
dehydration, electrolyte and fluid imbalances, and metabolic derangements such as 
hypokalemia and metabolic alkalosis.  Diarrhea can cause fluid and electrolyte losses, 
dehydration and metabolic alkalosis.  Constipation and obstipation (severe constipation) 
can develop after chemotherapy begins and can last for several weeks.  Stomatitis and 
mucositis (inflammation of the mucous membrane of the entire alimentary tract) are very 
common side effects of chemotherapy.  Serious complications may include cardiac 
toxicity, nephrotoxicity, and hepatoxicity (Bloch 1998). 
 The purpose of chemotherapy is to eliminate leukemia cells; however, in the 
process developing blood cells are eliminated as well.  This results in a deficiency of red 
blood cells, phagocytes, and platelets (Leukemia Society of America 1999a; The 
Leukemia and Lymphoma Society 2000).  The lowest value that blood cell levels fall to 
is called the nadir.  Platelets and white blood cells will reach their nadir in 7 to 14 days, 
but red blood cells may not reach a nadir for several weeks (American Cancer Society 
2001).  A transfusion of red blood cells or platelets may be required.  Antibiotic therapy 
also may be required with the reduction in phagocytes as this can cause an infection.  
After several weeks, blood cell production often returns to normal.  Blood cells counts 
will slowly approach normal levels.  When this occurs and leukemia cells cannot be 
identified in the blood or bone marrow, the patient is in remission (Leukemia Society of 
America 1999a; The Leukemia and Lymphoma Society 2000).   
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Radiation 
 Side effects of radiation may vary according to dose, site of administration, and 
individual response.  When the gastrointestinal tract is part of the radiation field, 
problems with nutrition should be expected.   Side effects of radiation may include the 
following: nausea, vomiting, diarrhea, anorexia, stenosis, radiation enteritis, 
malabsorption, anosmia (blunted taste and smell), difficulty or pain with swallowing or 
chewing, loss of taste, dry mouth, mucositis, dental decay, osteoradionecrosis, oral 
infections, trismus, dysphagia, dysgeusia, fatigue, strictures, and fistulas (Bloch 1998). 
Bone Marrow Transplant 
 A risk after a bone marrow transplant is graft versus host disease (GVHD).  
GVHD occurs in approximately 30% of allogeneic graft recipients who have human 
leukocyte antigens (HLA)- identical donors.   Autologous graft recipients occasionally 
develop GVHD, but the disease is usually cured with a short course of 
immunosuppression.  Immunosuppressant drugs are used at the time of the BMT and for 
a minimum of six months after the transplant to prevent GVHD.  The incidence and 
severity of GVHD increases for older patients, patients with unrelated or mismatched 
family donors, and patients who do not tolerate sufficient prophylactic drug therapy.  In 
15% of recipients, there are long-term complications that include poor engraftment with 
associated immunodeficiency and restrictive and obstructive lung disease.   Cataracts, 
aseptic bone necrosis, retarded growth, gonadal and ovarian failure, and tooth decay are 
other possible complications (Lenssen 1998).    
There is also a chronic form of GVHD, which develops 70 to 400 days (or more) 
after allogeneic BMT in 30% of patients with HLA-identical sibling donors and in as 
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many as 70% of patient with unrelated donors.  Several types of medications may be used 
in treating or preventing GVHD, including chemotherapy agents, immunotherapy and 
biological response modifiers, antimicrobials, and immunosuppressants, which add more 
side effects to the overall procedure (Lenssen 1998).   
Total Parenteral Nutrition and Cancer 
 Total parenteral nutrition has been the standard used with cancer patients due to 
concerns of infection, bleeding, and intolerance with enteral feeding.  In 1999, Ford and 
Pietsch conducted a study with children on home enteral feeding after chemotherapy or 
bone marrow transplantation.  The researchers found that the tube feedings were well 
tolerated, there were minimal complications, and costs were reduced when compared 
with TPN.  The conclusion reached was that tube feedings should be considered before 
TPN in children after intensive chemotherapy or BMT (Ford and Pietsch 1999).     
Several studies have been conducted with TPN and chemotherapy.  Chan and 
Blackburn (1999) reviewed eight prospective randomized clinical trials, and concluded 
that there was no overall advantage in survival of those receiving nutrition support, but 
the combination of drugs used for the chemotherapy were ineffective.  The overall 
conclusion reached was that TPN during chemotherapy should only be used for patients 
with hypoalbuminemia or weight loss of more than 10% who are responsive to 
chemotherapy (Chan and Blackburn 1999). 
Nosocomial Infections 
 Infections that develop in a hospital or are produced by microorganisms acquired 
during the hospital stay are called nosocomial infections.  Most nosocomial infections are 
detectable while the patients are still in the hospital; however, the onset of a disease could 
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occur after a patient has left the hospital.  Infections that the patient has upon admission 
are not considered nosocomial, but rather community acquired unless the patient received 
the infection from a previous hospitalization (Brachman 1998).   
 There are both preventable and nonpreventable nosocomial infections.  Preventable 
infections occur in a situation that could have been altered in order to prevent the 
infection from occurring.  An example of this is hand washing between contacts of 
urinary collection equipment from patients.  It is estimated that 30% of all nosocomial 
infections are preventable.  A nonpreventable infection is one that will occur regardless 
of the precautions taken to protect the patient (Brachman 1998). 
 It is estimated that 19,000 deaths occur nationwide annually that are directly 
attributable to nosocomial infections.  In approximately 58,000 deaths, nosocomial 
infections contributed but were not the only cause.  These estimates place nosocomial 
infections just below the tenth leading cause of death among the U.S. population 
(Martone et al. 1998).   
The major types of nosocomial infections and the percentages they represent of 
the total are urinary tract infection (42%), surgical wound infection (24%), pneumonia 
(10%), bacteremia (5%), and other (19%) (Gaynes 1998).  The average length of 
extended hospital days per infection is 1.0, 7.3, 5.9, 7.4, and 4.8, respectively (Martone et 
al. 1998).   
Parenteral Nutrition 
 There are an estimated 30 million patients who receive transfusion therapy each 
year.  Transfusion therapy can be fluid and electrolyte replacement, blood transfusion, 
hemodialysis, IV drug administration, intraarterial cancer chemotherapy, and total 
 42
parenteral nutrition.  Nationwide there are 50,000 to 100,000 patients who will obtain 
blood stream infections each year.  Blood stream infections can come from the 
intravascular device or contaminated infusate.  Parenteral fluids can become 
contaminated during administration in the hospital.  Culture surveys conducted on 
already in-use IV fluids, demonstrated a 1% to 2% contamination rate (Maki and Mermel 
1998).  Catheter-related sepsis may be caused from inappropriate technique of the line 
placement, poor catheter care, or a contaminated solution (Fuhrman 1998). 
Neutropenia 
 “Neutropenia is the most important factor predisposing to infections in leukemic 
patients, although not the only one” (Bassan 1996, 258).  “Neutropenia refers to an 
absolute blood neutrophil count (total lymphocyte count x percent of neutrophils) that is 
less than two standard deviations below the normal mean” (Dale 1995, 815).  The risk of 
infection is inversely correlated with this count.  As the duration of neutropenia increases, 
so will the frequency of infections (Bassan 1996). The concentration of neutrophils in the 
blood is reduced with age.  Adults, age 70 years and older, are more likely to develop 
neutropenia with severe inflammation or infections.  Patients who have neutropenia 
generally present with fever, sore throat, and inflammation of the skin or mucous 
membranes (Dale 1995).      
 
Metabolic Changes and Cancer 
 There are several possible metabolic changes that are brought about by cancer.  
The energy expenditure in cancer patients is not always elevated.  It is estimated that one 
third of cancer patients are hypometabolic, one third are normometabolic, and one third 
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are hypermetabolic.  “Increased resting energy expenditure may occur in patients with 
small cell carcinoma, leukemia, and lymphoma” (Bloch 1993, 214).  In protein 
metabolism, cancer causes increased turnover of whole-body protein, increased rate of 
protein synthesis of protein in the liver, decreased rate of synthesis in the skeletal muscle, 
and an increase in overall skeletal muscle breakdown.  Cancer patients who have a 
progressive disease will metabolize more fat than those who do not have a progressive 
disease.  It is frequent for cancer patients to have a decrease in total body fat, which may 
be attributable partly to insulin resistance or deficiency.  Glucose metabolism may be 
altered and glucose intolerance can occur.  There is decreased insulin sensitivity and 
responsiveness to insulin (Bloch 1993).       
 
Nutritional Assessment of the Cancer Patient 
 
Definition and Purpose 
 Nutritional assessment has been defined as, “an evaluation of the nutritional status 
of individuals or populations through measurement of food and nutrient intake and 
evaluation of nutrition-related health indicators” (Lee and Nieman 1996, 3).  The U.S. 
Department of Health and Human Services explained nutritional assessment as, “the 
measurement of indicators of dietary status and nutrition-related health status to identify 
the possible occurrence, nature and extent of impaired nutritional status” (Lee and 
Nieman 1996, 3).  The American Dietetic Association describes nutritional assessment 
as, “a comprehensive approach, completed by a registered dietitian, to defining 
nutritional status that uses medical, nutrition, and medication histories; physical 
examination; anthropometric measurements; and laboratory data” (Posthauer et al 1994, 
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838).  The purpose of nutritional assessment according to the World Health Organization 
is to improve human health (Lee and Nieman 1996).   
Components of Nutritional Assessment 
Nutritional assessment of the cancer patient is similar to the assessment of any 
other hospitalized patient (D’Angelo 2000).   In a nutritional assessment there are four 
different methods used to collect data.  These include anthropometric, biochemical, 
clinical, and dietary.  “ABCD” is the mnemonic that is often used to help remember these 
methods (Lee and Nieman 1996).     
Anthropometric 
 The two types of anthropometric measurements are growth and body composition 
measurements.  The most commonly used measurements of growth are height and body 
weight.  Current and usual weight of the patient must be known to assess changes in body 
weight.  Changes in weight may be due to changes in protein status, water, minerals, 
and/or body fat content.  For adults, height/weight ratios or body mass indices are 
commonly used (Gibson 1990).  Quetelet’s Index (weight/height2) is the most frequently 
used (Gibson 1990; Lee and Nieman 1996).   
 Body composition measurements include assessing body fat and fat free mass.  
These measurements can be done by skinfold thickness and circumference 
measurements.  Skinfolds can provide an assessment of subcutaneous fat stores and 
therefore overall total body fat.  Circumference of muscle area provides an estimate of 
protein reserves in the body, and overall protein status (Gibson 1990).  
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 For the hospitalized adult cancer patient, weight is a very important measure. 
Weight loss greater than 10% is seen in 45% or more cancer patients.  Cancers with the 
lowest frequency of weight loss (31% to 40%) include acute nonlymphocytic leukemia, 
breast, sarcoma, and non-Hodgkin’s lymphoma.  Colon, prostate, and lung cancers have 
an intermediate frequency of weight loss (48% to 61%).  Pancreas and stomach cancers 
have the highest frequency of weight loss (83% to 87%).  Placing patients at nutritional 
risk is involuntary weight loss of 5% to 10% in a period of one to six months (Bloch 
1998).    
 Cancer patients also commonly experience changes in body composition, which 
includes loss of subcutaneous fat stores and loss of lean body mass.  Bloch reports loss of 
muscle tissue can lead to fatigue, weakness, increased risk of thrombosis, decubiti, 
muscle atrophy, compromised respiratory function, and gastrointestinal symptoms (Bloch 
1998).  Anthropometric measurements for the cancer patient may include body weight, 
weight-height ratio, triceps skinfold thickness, and midarm muscle circumference 
(Herrmann, Fuhrman, and Borum 1998).  Anthropometry measures for muscle mass may 
be useless due to visible signs of wasting and fat store depletion (Bloch 1998; Herrmann, 
Fuhrman, and Borum1998).  Anthropometry would be more useful if the patient is 
followed long term in an outpatient setting (Bloch 1998).   
Biochemical  
  Biochemical tests can provide the most quantitative and objective data when 
compared with the other methods of nutritional assessment.  Biochemical tests usually 
detect nutrient deficiencies before anthropometric or clinical signs appear (Lee and 
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Nieman 1996). There are two general groups of biochemical tests, which are static tests 
and functional tests.  Static tests are measures of nutrients or its metabolite taken in the 
blood, urine, or body tissue (Lee and Nieman 1996; Gibson 1990).   The most readily 
available static tests include serum measurements of albumin, calcium, or vitamin A.  
These tests do have some limitations.  They may not reflect overall nutritional status, 
because they only measure a tissue or fluid that was sampled (Lee and Nieman 1996).  
Many different factors may confound the results of static tests including recent dietary 
intake, exercise, age, sex, infections, weight loss, inflammatory stress, medications, 
nutrient interactions, and hemolysis (Gibson 1990).   
Functional tests measure the extent of functional consequences of a specific 
nutrient deficiency (Lee and Nieman 1996; Gibson 1990).   Examples of functional tests 
include impairment of immune status from protein-energy malnutrition, assessment of 
vitamin A status through dark adaptation, and assessing vitamin B6 status through urinary 
excretion of xanthureic acid in response to consumption of tryptophan.  A limitation of 
functional tests is that they are not specific.  They may indicate general nutrient 
deficiencies, but do not identify specific nutrient deficiencies (Lee and Nieman 1996).  
Also non-nutritional factors may influence functional tests (Gibson 1990).   
For assessment of cancer patients, nutritional biochemical tests measuring visceral 
protein status and blood levels of electrolytes and minerals should be measured and 
monitored (Bloch 1998).  Visceral protein tests include thyroxine-binding prealbumin 
(transthyretin), transferrin, retinol binding protein, and albumin (Bloch 1998; Harrison 
and Brennan 1995). Transferrin has a half-life of 8 to 10 days, responding more rapidly to 
nutrition repletion or depletion.  Prealbumin has a half-life of 2 to 3 days, responding 
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quickly to nutritional status.  Retinol-binding protein has the shortest half-life of 10 to 12 
hours (Harrison and Brennan 1995). 
Serum albumin has the limitations of assuming a steady state, which is not true 
during acute illnesses, a long half-life of about 20 days, and levels are affected by 
hydration status (Harrison and Brennan 1995).  Malnutrition, malabsorption, 
overhydration, nephrotic syndrome, protein-losing enteropathy, pregnancy, burns, and 
chronic illness may cause hypoalbuminemia.  Hyperalbuminemia is seen in patients with 
dehydration or patients taking anabolic steroids (Farkas and Hyde 1996).  A decrease in 
serum albumin is correlated with increased morbidity and mortality (Herrmann, Fuhrman, 
and Borum 1998).  The normal range for adults is 3.5-5.0 grams per deciliter (Farkas and 
Hyde 1996).   
“White blood cell count and differential is one of the most widely performed 
clinical laboratory tests” (Jordan 1996, 309).  White blood cell (WBC) count is an actual 
count of the number of leukocytes in a given amount of blood.  The reference adult range 
is 4.8-10.8 x 109 cells per liter.  Included in the WBC differential are neutrophils, bands, 
lymphocytes, monocytes, basophils, and eosinophils.  Each component in the WBC 
differential is measured as a percentage, and the percentages must add up to 100% 
(Jordan 1996).  Appendix F provides a table of the normal white blood cell count and 
differential.  White blood cells have an average six-hour lifespan (American Cancer 
Society 2001).  Patients who have chronic leukemia will always have an increase in 
WBC.  Patients with acute leukemia may have a low, normal, or high WBC.  
Occasionally, the WBC may be several times higher than an average count (The 
Leukemia and Lymphoma Society 2001b).  For patients with a low WBC, hematopoietic 
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growth factors may be administered in a drug form.  These drugs help the bone marrow 
to recover more quickly and reduce the risk of serious infections (American Cancer 
Society 2001).      
The adult range for total lymphocyte count (TLC) is 20-40% (Jordan 1996).  A 
decrease in TLC can reflect nutritional depletion, and repletion can be reflected by an 
increase in TLC (Harrison and Brennan 1995).  The equation used for TLC and 
nutritional status is % lymphocytes multiplied by WBC divided by 100 equals TLC.  For 
an indication of nutritional status, a TLC of 1500 to 1800 mm3 reflects mild depletion, 
900 to 1500 mm3 reflects moderate depletion, and less than 900 mm3 reflects severe 
depletion.  TLC is not an absolute indicator of nutritional status.  Patients who have 
leukemia or an infection will have increased levels of TLC.  TLC will decrease with 
cancer, metabolic stress, steroid therapy, and after surgery (Hopkins 1993).   
Platelets in the blood promote clot formation.  The average platelet lifespan is 8 to 
12 days.  Thrombocythemia is an excess of platelets, which can be seen in patients who 
have chronic myelogenous leukemia.  Thrombocytopenia is a low platelet count.  
Metastatic cancers, leukemia, and aplastic anemia may reduce the production of platelets 
(Groce and Carter 1996).  For low platelet counts, platelet transfusions may be given.  
Transfused platelets only last a few days and after several platelet transfusions, an 
immune reaction may develop that destroys donor platelets.  A platelet growth factor may 
also be given as a drug for people with thrombocytopenia (American Cancer Society 
2001).  Approximately one-third of platelets can be found in the spleen.  Enlargement of 
the spleen will cause platelets to drop.  In leukemia patients, the spleen may be removed 
to improve cells counts.  If the spleen is removed, thrombocythemia will occur, but will 
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subside within one month (Association of Cancer Online Resources 2001).  The normal 
adult range for platelets is 140,000-440,000 per microliter (Groce and Carter 1996).    
Clinical 
 Clinical assessment consists of the medical history and physical examination.  
The medical history can be obtained from the patient or from the medical record.  
Medical history usually includes a description of the patient, any relevant environmental, 
social and family factors (Gibson 1990).  The physical examination has been defined as, 
“those changes, believed to be related to inadequate nutrition, that can be seen or felt in 
superficial epithelial tissue, especially the skin, eyes, hair, and buccal mucosa, or organs 
near the surface of the body” (Gibson 1990, 579).    
   For the cancer patient, a detailed history of weight loss is very important.  The 
percentage of weight loss correlates with complications and mortality.  A history of 
bacterial and viral illness suggests immune dysfunction.  Specific changes to note during 
the physical examination include general muscle wasting, peripheral edema, poor wound 
healing, and neurologic changes (Herrmann, Fuhrman, and Borum 1998).   
 There are several screening and assessment tools that may be used to determine 
nutrition status.  The Subjective Global Assessment (SGA), Patient-Generated Subjective 
Global Assessment (PG-SGA), and the Oncology Screening Tool are forms being utilized 
in different clinical settings.  These forms identify the patient’s nutritional risk category.  
In the SGA, there are five components of history and three components of physical 
examination.  The history includes current weight and weight history, current and usual 
dietary intake, gastrointestinal symptoms, performance status, and metabolic 
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requirements.  The physical examination includes muscle, fat, and fluid status.  After 
assessing these aspects, the patient is categorized as well nourished, moderately or 
possibly malnourished, or severely malnourished (Bloch 1998).   
 Dietary 
 Nutrient intake data are very valuable for nutritional assessment, especially when 
used with anthropometric, biochemical, and clinical data (Lee and Nieman 1996).  There 
are two main methods for measuring food consumption of individuals.  Quantitative daily 
consumption methods include recalls or records designed to measure the quantity of food 
consumed over a one-day period.  The second group of methods consists of dietary 
history and the food frequency questionnaire.  Dietary intake data are often compared to 
The Recommended Dietary Allowances, food groups, dietary guidelines, or the United 
States Department of Agriculture’s Food Guide Pyramid (Gibson 1990).   
 There are several categories that may need to be assessed in the cancer patient.  
Some of these include, dietary habits, patterns, current practices, food aversions, changes 
in preferences, identifiable taste changes or sensations, and actual intake compared to 
food prepared or on the plate.  Diet histories are more labor intensive, and should be used 
only with high-risk patients.  Food frequency questionnaires are not as useful for 
individuals, but more for a group of people as they usually encompass a global intake of 
food.  The most useful form for the hospitalized cancer patient would be a current or 
recent food intake history.  This could be accomplished in any form including a calorie 
count. A general recent diet history gives the dietitian a more accurate picture of the 
patient’s overall food and nutrient status (Bloch 1999). 
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The Role of the Nutrition Support Team 
 
 It has been almost three decades since the first nutrition support teams were 
started. There was a rapid growth of nutrition support teams during the 1970’s and early 
1980’s; however, recently the growth of new teams has tapered off.  It is almost universal 
that the nutrition support team consists of at least one physician, nurse, dietitian, and 
pharmacist (Wesley 1995).  The purpose of the nutrition support team is simply to 
provide nutritional care.  Wesley (1995, 219) identified three ways that this purpose is 
accomplished, “(1) identification of patients who are nutritionally impaired, (2) 
performance of a nutrition assessment that can adequately guide nutrition therapy, and (3) 
provision of safe and effective nutrition support”.    The role of nutrition support teams 
across the country includes inpatient consultation, educational programs, quality 
assurance, research, and home nutrition support programs  (Wesley 1995).   
 There are several generally recognized cost-effective benefits of a nutrition 
support team, which include the following (Wesley 1995, 220): 
 Recognition and treatment of malnutrition 
 Reduction of mechanical and metabolic complications of parenteral 
and enteral nutrition 
 Reduction in morbidity and mortality 
 Reduction in the cost of providing specialized nutrition support by 
facilitating the appropriate use of enteral and parenteral therapies 
 Provision for more cost-effective selection of products 
 Reduction in costly wastage of formula 
 Selection of appropriate nutrition support equipment and devices 
 Reduction in length of stay and costs to the hospital 
 Reduction in liability exposure 
 Selection and monitoring of appropriate laboratory test 
 
The dietitian is a valued member of the nutrition support team.  Research has 
demonstrated that patients achieve nutrition goals more quickly when dietitian 
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recommendations were followed.  The dietitian is the key team member for monitoring 
nutritional progress of the patient as well as ongoing assessment for readiness to progress 
to another type of nutritional support or to discontinue therapy (Skipper and Perlmutter 
1992).       
 
The Role of the Registered Dietitian in Nutrition Support 
 
American Dietetic Association 
 
 The role of the dietitian in enteral nutrition is a well-acknowledged skill, but the 
role of the dietitian in parenteral nutrition is less recognized by medical staff and other 
health care professionals (Gilmour and Glencorse 1998).  The Position Statement of The 
American Dietetic Association regarding the role of dietitians in nutrition support states,  
It is the position of The American Dietetic Association that a 
registered dietitian (RD) with competency in nutrition support is 
qualified to assume responsibility for the assessment, planning, 
implementing, and monitoring of enteral, parenteral, and specialized 
oral therapies in patient care (The American Dietetic Association 
1997, 302).   
Nutrition support has evolved over the years and registered dietitians have developed 
their skills to keep up with this rate of change.  The American Dietetic Association has 
delineated the role of the registered dietitian in nutrition support, which is listed in  
Table 4. 
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Table 4.  Current Role of the Registered Dietitian in Nutrition Support  
 Identifies patients at nutritional risk 
 Performs periodic assessment of patients receiving nutrition support 
 Acts as the advocate for all aspects of nutrition care 
 Participates in the design, implementation, and monitoring of enteral and 
parenteral nutrition regimens 
 Provides for nutritionally complete transitional feeding 
 Documents nutrition care plans 
 Provides education to patients, families, and health care professionals 
 Translates the nutrition care plan into understandable language 
 Participates in the design, implementation, and monitoring of home enteral and 
parenteral nutrition regimens 
 Participates in local, regional, national, and international programs 
 Promotes the importance of nutrition and dietetics services to providers and 
government to enhance reimbursement for these services 
 Documents for proper coding both nutrition services and diagnoses to increase 
reimbursement 
 Participates in research studies 
 Participates in studies designed to examine clinical outcomes for nutrition 
services in specific populations 
 
Source:  The American Dietetic Association, 1997.  Position of The American Dietetic 
Association: The role of registered dietitians in enteral and parenteral nutrition support.  Journal 
of the American Dietetic Association 97:302-304.    
 
 A survey conducted in 1995, by Gilmour and Glencorse (1998), demonstrated that 
there is a need for dietitians to be more involved in parenteral nutrition and also that 
dietitians are increasing their involvement.  According to their survey, 99% of dietitians 
felt they had a role to play in parenteral nutrition.  A total of 83% of the dietitians 
surveyed felt they would like to be more involved with parenteral nutrition.  Doctors are 
still the most common prescribers of TPN, despite the fact that routine training is not 
received in nutritional assessment, nutrient calculations, and prescribing.  According to 
the survey, 50% of dietitians knew of cases where medical staff prescribed inappropriate 
parenteral nutrition (Gilmour and Glencorse 1998).   
 In 1996, a study by Mueller et al., reported the most frequent response to the 
dietitian’s role in the decision to provide parenteral nutrition was to “recommend” 
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parenteral nutrition to a physician or other health care professional.  Of the total 
respondents of this study, 37% wrote parenteral nutrition orders some or all of the time.  
The study also found that specialists were more likely to write orders than clinicians or 
managers, however educational level and length of registration did not affect the 
likelihood of those writing orders (Mueller, Colaizzo-Anas, and Shronts 1996). 
 Registered dietitians do have the skills to participate in parenteral nutrition 
regimens.  “Registered dietitians with competency in nutrition support have acquired 
unique skills, through both clinical experience and formal training, to plan, implement, 
and monitor any combination of enteral and parenteral therapies” (The American Dietetic 
Association 1997, 302).  The American Dietetic Association has pronounced the RD to 
be “the primary resource for the choice of appropriate oral supplements, enteral formulas, 
and prescriptions of parenteral solutions” (The American Dietetic Association 1997, 
303).   
American Society for Parenteral and Enteral Nutrition 
 In 1986, the American Society for Parenteral and Enteral Nutrition published 
standards of practice for nutrition support dietitians.  The standards were revised in 1990, 
and revised again in 1999 (Appendix G).  There are nine general standards described as 
well as several specifics for each standard.  The standards included are as follows: 
competency; screening and assessment; medical nutrition therapy care plan; 
implementation; monitoring; reassessment, updating, and termination of medical nutrition 
therapy care plan; administrative management; education, training, and communication; 
and research.  These standards were developed as general guidelines for registered 
dietitians in nutrition support (ASPEN 1993).  “Use of these standards is expected to 
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promote quality patient care and improve the effectiveness of health care activities”  
(Winkler 1993, 1113).   
 Winkler conducted a study about the importance and value of the ASPEN 
standards of practice to dietitians in 1993.  Of the total respondents, 68% reported using 
the ASPEN standards of practice.  All the standards of practice had high importance 
ratings and were used widely, giving validity to the standards (Winkler 1993). 
 
The Need for Outcomes Research  
 
 For dietitians, documenting outcomes is essential to compete in the ongoing 
health care economic battle.  “Specifically, clinical dietitians need to do outcomes 
research and report their results” (Eck et al. 1998, 452).  Eck and colleagues (1998) 
conducted a survey of registered dietitians in clinical practice, and found that dietitians 
have an interest in research, however the interest does not produce more involvement or 
publication.  Eck et al. (1998, 457) summarized the need for outcomes research,  
Dietetics research and dietetics practice currently operate as separate 
entities, but research must become a key component in clinical 
dietetics practice.  The goal of meshing the 2 areas is not only possible 
but expedient to the successful growth of our profession in the rapidly 
changing health care environment.     
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Methodology 
Introduction 
 
 Since the 1997 merger of the two organizations, there has been a variance of 
dietetic practice at the different hospital sites.  This inconsistency of practice has been 
especially noted in the area of nutrition support.  At both the hospitals patients on TPN 
were classified as high nutrition risk patients, and the protocol is for the registered 
dietitian to document in the medical record a follow up chart note every four days.  It is 
generally understood that at site A, the dietitians allowed pharmacy to follow patients on 
TPN, whereas at site B the dietitians followed patients on TPN more closely.  The health 
system is considering standardizing the practice of nutrition support and the role of the 
dietitian at these sites.  An objective of this research was to determine if the amount of 
dietitian follow up in the area of nutrition support affects patient outcomes in these two 
institutions.  Other objectives were to determine if the amount of dietitian involvement 
would influence the length of stay, length of TPN administration, and protein status or 
weight gain of leukemia patients (hypotheses 1-4).   
Data Collection 
Inclusion Criteria 
Medical records of 115 adult patients (18 years and older) with the diagnosis of 
leukemia and who had received TPN were retrospectively reviewed.  Medical records 
included in the study were individuals with the diagnosis of leukemia and TPN 
discharged from January 1, 1997 through December 31, 2000 at site A and site B.  
Outpatient records and data were not utilized.   
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Because parenteral nutrition is not always coded by the ICD-9-CM codes in the 
computer system, a data analyst from a performance improvement team with the health 
system created the list of patients by combining the billing code for TPN and the ICD-9-
CM codes for leukemia.  Data on these patients were collected by a review of the medical 
record using the form in Appendix H.  The health system’s Human Subjects Review 
Board as well as the University of Wisconsin-Stout Institutional Review Board approved 
this study.  (See Appendix I for approval forms.) 
Data Collection Instrument 
The data collection form is divided into four major sections relating to admission 
information, dietitian involvement, TPN prescription, and lab values.  Adjustments for 
comorbidities were made using a translation of the Charlson Comorbidity Index 
(Charlson et al. 1987) in Appendix A into the ICD-9-CM codes (Deyo, Cherkin, and Ciol 
1992) found in Appendix B.  Severity of disease was determined using the clinical 
staging of the leukemia.  Dietitian involvement was defined by charting completed by the 
dietitian in the medical record.  A follow up note by the dietitian was only counted as a 
follow up if the note contained more information than just calorie count data.  A change 
in the TPN prescription by the dietitian was only recorded if the dietitian recommended a 
change within three days of TPN initiation.  If a lab value or weight was not taken on the 
admission or discharge day, then the closest value taken to the day was recorded.  For the 
weight status, if calculated dry weight was available it was utilized.  The percent ideal 
body weight was calculated using the Hamwi equation (Lysen 1997).  The Hamwi 
equation for males is 106 pounds for the first 5 feet plus 6 pounds for every one-inch 
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above five feet.  For females the equation is 100 pounds for the first 5 feet plus 5 pounds 
for every one-inch above 5 feet.    
Statistical Methods 
Descriptive analyses included tabulating means, medians and percentages.  
Associations between variables were explored using Pearson and Spearman correlational 
analyses.  Differences between the two hospital sites were tested by chi-square analyses 
or t-tests.  Statistical and correlational analyses were performed with SPSS, version 10.0 
(1999, Chicago, IL).  The level of significance for all tests was p ≤ 0.05.   
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Results 
Study Sample 
During the four-year time span (1997-2000), 130 patients with leukemia were 
admitted and given TPN.   The study sample included 115 of these patients.  The 
remaining 15 patients were excluded from the study due to unavailability of the medical 
records.   A series of chi-square and t-tests were preformed to test for group difference 
between research subjects and persons excluded from the study.  Although complete 
medical data were not available, existing computerized archival data was used to obtain 
the following variables: age; gender; year of admission; type of leukemia; length of stay; 
and the four lab values of albumin, total lymphocyte count (TLC), platelets, and white 
blood cells.  Initial analysis with the 15 patients not included in the study revealed 
significant differences only for length of stay and TLC on discharge.  However, one 
subject in this group was an extreme outlier due a long length of stay.  Removing that 
subject from the analyses left significance only for TLC on discharge with an observed 
mean of 7.89% for those not included in the group compared to an observed mean of 
17.01% (p=0.021) for those who were included.   
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Description of the Subjects 
 A total of 115 patients, 86 from site A and 29 from site B, were included in the 
study.  Table 5 delineates the age of the subjects at the individual sites and in the 
combined sample.   The results of the t-test demonstrated significant mean differences for 
age between site A and site B (p<0.001), with site B having an older population.     
Table 5. Subject Age  
Hospital site Age in years 
Site A Site B Combined 
N 86 29 115 
Minimum 
 
19 22 19 
Maximum 79 92 92 
 
Mean 
± SD 
42.95 
(15.37) 
60.10 
(15.67) 
47.28 
(17.10) 
t-value = 5.17, df = 113, p <0.001 
 
 Table 6 identifies the frequency and percent of males and females at each site and 
that of the total sample.  The chi-square test revealed significant differences between the 
two sites for gender (p<0.001), with site A having more males and site B having more 
females.       
Table 6. Subject Gender 
Hospital site 
Site A Site B Combined 
Gender 
Frequency Percent Frequency Percent Frequency Percent 
Male 53 61.6 8 27.6 61 53.0 
Female 33 33.8 21 72.4 54 47.0 
Total 86 100.0 29 100.0 115 100.0 
χ = 10.09, df = 1, p <0.001 
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Table 7. Subject Type of Leukemia 
Hospital site 
Site A Site B Combined 
Type of 
leukemia 
Frequency Percent Frequency Percent Frequency Percent 
AML 46 53.5 21 72.4 67 58.3 
ALL 9 10.5 1 3.4 10 8.7 
CML 24 27.9 3 10.3 27 23.5 
CLL 7 8.1 4 13.8 11 9.6 
χ = 6.14, df = 3, p =0.105 
 
  
Table 7 classifies each type of leukemia by individual sites and the entire sample.  
The chi-square test did not demonstrate significant differences between the two sites for 
the type of leukemia for which the patient was diagnosed.  The total number of patients 
diagnosed with AML, ALL, CML, and CLL were 46, 9, 24, and 7, respectively at site A; 
and 21, 1, 3, and 4, respectively at site B.   
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Table 8. Subject Stages of Leukemia    
Hospital site 
Site A Site B Combined 
Stage of leukemia  
Frequency Percent Frequency Percent Frequency Percent 
AML  
Remission 15 32.6 0 0 15 22.4 
Recurrent/Refractory 30 65.2 21 100.0 51 76.1 
Total 45 97.8 21 100.0 66 98.5 
Missing 1 2.2 0 0 1 1.5 
Total 46 100.0 21 100.0 67 100.0 
ALL  
Remission 4 44.4 0 0 4 40 
Recurrent/Refractory 5 55.6 1 100.0 6 60 
Missing 0 0 0 0 0 0 
Total 9 100.0 1 100.0 10 100.0 
CML  
Chronic 15 62.5 1 33.3 16 59.3 
Accelerated 1 4.2 0 0 1 3.7 
Blastic 5 20.8 1 33.3 6 22.2 
Refractory 1 4.2 0 0 1 3.7 
Total 22 91.7 2 66.7 24 88.9 
Missing 2 8.3 1 33.3 3 11.1 
Total 24 100.0 3 100.0 27 100.0 
CLL  
Stage 3 1 14.3 0 0 1 9.1 
Missing 6 85.7 4 100.0 10 90.9 
Total 7 100.0 4 100.0 11 100.0 
χ = 16.67, df = 6, p =0.011 
 
Table 8 identifies the frequency and percent for each of the stages of the four 
types of leukemia.  Results from the chi-square test revealed that there was a significant 
difference in leukemia stages between the two sites (p=0.011), with site A representing 
more of the possible stages for AML, ALL, and CLL.  Site B had no patients who were in 
remission whereas site A had 19 patients in remission.   
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Table 9.  Subject Charlson Comorbidity Index 
Hospital site 
Site A Site B Combined 
Charlson 
Comorbidity 
Index 
Frequency Percent Frequency Percent Frequency Percent 
0 70 81.4 17 58.6 87 75.7 
1 9 10.5 5 17.2 14 12.2 
2 4 4.6 4 13.8 8 6.9 
3 3 3.5 0 0.0 3 2.6 
4 0 0.0 3 10.4 3 2.6 
Total 86 100 29 100 115 100 
χ = 14.82, df = 4, p = 0.005 
 
Table 9 identifies the frequency and percents of the Charlson Comorbidity Index 
scores at each site and both the sites combined.  Results from the chi-square test 
confirmed that the Charlson Comorbidity Index was significantly different between the 
two sites (p=.005), with site B having patients with  higher comorbidity scores.     
 
Table 10.  Subjects Expiring During Hospitalization 
Hospital site 
Site A Site B Combined 
Expired 
Frequency Percent Frequency Percent Frequency Percent 
No 64 74.4 17 58.6 81 70.4 
Yes 22 25.6 12 41.1 34 29.6 
χ = 6.14, df = 3, p =0.107  
 
 
 Frequencies and percents of subjects expiring are shown in table 10.  A significant 
difference was not found between the numbers of patients expiring at the two sites using 
a chi-square test.  
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Research Hypotheses 
 The purpose of this study was to investigate if timely dietitian follow up was 
associated with the outcomes of decreased length of stay, decreased duration of TPN 
administration, improved protein status, and weight gain for leukemia patients.  The 
following tables identify differences across the variables related to the hypotheses.  Table 
11 identifies the means and standard deviations of the percent of expected follow-ups 
performed.  The t-test indicated that a significantly greater number of dietitian follow ups 
occurred at site B.   
Table 11.  Percent of Dietitian Follow ups Performed 
Hospital site Percent of RD 
follow ups Site A Site B Combined 
N 85 29 114 
Minimum 0 0 0 
Maximum 233.33 342.86 342.86 
Mean 
± SD 
27.10  
(39.09) 
73.33 
(62.48) 
38.86 
(50.12) 
t-value = 4.67, df = 112, p <0.001 
 
A significant difference was not found between the two sites for length of 
inpatient hospital stay.  Table 12 identifies range and mean stay in days.   
Table 12. Length of Stay 
Hospital site Length of stay 
in days Site A Site B Combined 
N 86 29 115 
Minimum 6 3 3 
Maximum 83 90 90 
Mean 
± SD 
34.27 
(14.16) 
32.03 
(21.78) 
33.70 
(16.34) 
t-value = -0.635, df = 36.31, p = 0.609 
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A significant difference was found between the two sites for the number of days 
on TPN, with site A having a longer duration of TPN (p =0.007), 17.9 days compared to 
site B with 12.2 days.  Site A had one patient who was an outlier with 74 days on TPN 
and that patient was removed from the analyses.  The median and mode at Site B were 8 
and 6, respectively.  At site A, the median was 18 and the mode was 14.  The results from 
the t-test are listed in table 13.   
Table 13. Number of Days on TPN 
Hospital site Number of days 
on TPN Site A Site B Combined 
N 83 29 112 
Minimum 1 1 1 
Maximum 46 37 46 
Mean 
± SD 
17.92 
(9.64) 
12.17 
(10.07) 
16.43 
(10.03) 
t-value = -2.73, df = 110, p = 0.007 
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Table 14 identifies the mean and range for the serum albumin values collected.  
Albumin has a half-life of approximately 20 days, indicating that a hospital stay of less 
than 20 days may not reflect changes in albumin.  To control for the shorter length of 
stay, only those with a length of stay greater than 20 days were evaluated.  The albumin 
change value was calculated by subtracting the discharge value from the admit value.  No 
significant difference was found between the two sites for the change in albumin.   
Table 14. Serum Albumin Values 
Hospital site Albumin on 
admit Site A Site B Combined 
N 74 20 94 
Minimum 1.6 1.5 1.5 
Maximum 4.4 4.3 4.4 
Mean 
± SD 
3.18 
(0.56) 
3.09 
(0.624) 
3.16 
(0.57) 
Albumin on 
discharge 
 
N 73 19 92 
Minimum 1.6 1.4 1.4 
Maximum 3.6 3.2 3.6 
Mean 
± SD 
2.77 
(0.39) 
2.4 
(0.46) 
2.69 
(0.44) 
Albumin 
change 
 
N 73 19 92 
Minimum -0.80 -0.40 -0.80 
Maximum 1.90 2.00 2.00 
Mean 
± SD 
0.42 
(0.55) 
0.69 
(0.69) 
0.48 
(0.59) 
t-value = 1.83, df = 90, p = 0.700 
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 Table 15 identifies the mean and range for the TLC values collected.  Because 
chemotherapy kills lymphocytes, only patients who did not receive chemotherapy were 
evaluated.  No significant difference was found for a change in TLC between the two 
sites.   
 
Table 15. Total Lymphocyte Count Values 
Hospital site TLC on admit 
Site A Site B Combined 
N 16 8 24 
Minimum 2.0 6.0 2.0 
Maximum 96.0 98.0 98 
Mean 
± SD 
22.35 
(24.87) 
46.38 
(38.48) 
30.36 
(31.43) 
TLC on 
discharge 
 
N 15 7 22 
Minimum 2.0 5.0 2.0 
Maximum 60.0 97.0 97.0 
Mean 
± SD 
15.67 
(17.68) 
33.00 
(31.46) 
21.19 
(23.66) 
TLC change  
N 15 7 22 
Minimum -38.00 -16.00 -38.00 
Maximum 40.00 30.00 40.00 
Mean 
± SD 
1.77 
(17.34) 
7.00 
(16.15) 
3.43 
(16.77) 
t-value = 0.673, df = 20, p = 0.509 
 
The range and mean weight lost in kilograms is identified in Table 16.  A t-test 
did not demonstrate a significant difference for weight change between the two sites.   
Table 16. Weight Change in Kilograms for Subjects 
Hospital site Weight lost in 
kg Site A Site B Combined 
N 82 27 109 
Minimum -17 -8 -17 
Maximum 32 17 32 
Mean 
± SD 
-1.46 
(5.67) 
-0.36 
(4.59) 
-1.18 
(5.43) 
t-value = .913, df = 107, p = 0.361 
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Table 17.  Correlations of Dietitian Involvement and Outcomes 
 Length of 
Stay 
 
 
 
n=114 
Total 
number of 
days on 
TPN 
 
n=111 
Difference 
between Alb 
on admit and 
dischargea  
 
n=91 
Difference 
between 
TLC on 
admit and 
dischargeb  
n=22 
Weight 
loss in 
Kg 
 
 
n=109 
Percent of 
RD 
Follow ups 
performedc 
Pearson 
Correlation 
 
Sig. (2-tailed) 
 
-0.146 
 
 
0.122 
 
-0.211* 
 
 
0.026 
 
-0.150 
 
 
0.156 
 
-0.074 
 
 
0.744 
 
 
0.080 
 
 
0.408 
 
 
a.Only patients with a length of stay ≥ 20 days were included in this analysis.   
b.Only patients who did not receive any treatment were included in this analysis.     
c. LOS divided by 4=expected number of RD follow ups.  Actual number of follow up notes divided by 
expected number of follow up notes x 100=percent of RD follow ups performed.   
 
Table 17 identifies the correlations between these variables for the research 
hypotheses.  The total number of days on TPN was the only variable that correlated with 
dietitian follow up.  Patients who had expired were left in these analyses for statistical 
power.  However, a partial correlation was used which controlled for survival to hospital 
discharge and no statistically significant changes were found from the above results.    
The primary null hypothesis of this research (Ho1) was that timely follow up 
documentation from the dietitian will not significantly influence the outcome of length of 
hospital stay.  A non-significant negative correlation was found with dietitian follow-up 
and the total number of days in the hospital.  Therefore, the null hypothesis must be 
accepted.   The primary alternate hypothesis (H1) was that timely follow up 
documentation would significantly decrease length of stay.  Thus, the alternate 
hypothesis was rejected.   
 The second null hypothesis (Ho2) was that timely follow up by the dietitian would 
not significantly influence the outcome of length of TPN.  A significant negative 
correlation was found with dietitian follow up and the total number of days on TPN.  
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Thus, the null hypothesis must be rejected.  The alternate hypothesis (H2), stating timely 
dietitian follow up will significantly decrease the length of TPN, must then be accepted. 
 The third null hypothesis (Ho3) asserts that timely dietitian follow up will not 
significantly influence the outcome of protein status.  The differences between admit and 
discharge for the lab vales of albumin and total lymphocyte count were used to determine 
protein status.    For both of the changes in albumin and TLC, non-significant negative 
correlations were found, indicating to accept the null hypothesis.  The alternate 
hypothesis (Ho3), states that dietitian follow up will significantly improve protein status.  
Thus, the alternate hypothesis must be rejected.   
 The fourth null hypothesis (Ho4) declares that timely follow up by the dietitian 
will not significantly influence the outcome of weight.  Using the difference in body 
weight from admission to discharge, a non-significant positive correlation was found 
indicating that the null hypothesis must be accepted.  The alternate hypothesis (Ho4), that 
timely dietitian follow up will significantly increase weight, must then be rejected.   
To examine the difference of dietitian follow up between the two sites, the fifth 
null hypothesis of this research (Ho5) was that dietitian involvement with TPN protocols 
would not be significantly different between the two institutions.  Dietitian involvement 
was defined by the percent of expected follow-ups performed by the dietitian.   The 
results of the t-test indicate that dietitian involvement was significantly different between 
the two sites (p<0.001).  Thus, the null hypothesis was rejected.   
The alternate hypothesis (H5) was that dietitian involvement with TPN protocols 
would be significantly different between the two sites.  Thus, the alternate hypothesis was 
not rejected.   
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Results From Other Data Collected 
Admission Information 
Data was also collected from the medical records on the reason for admission 
(principle diagnosis), the treatment received while in the hospital, and the number of 
readmissions during the four-year time span for each patient.  Table 18 identifies the 
reasons for admission for each of the sites and then the sites combined.  Chi-square test 
results identified a non-significant difference between the two sites.  Caution should be 
used when interpreting this table as the analyses is weak due to the low patient number in 
many of the cells. 
Table 18.  Principle Diagnosis of Subjects 
Hospital site 
Site A Site B Combined 
Diagnosis 
Frequency Percent Frequency Percent Frequency Percent 
AML 35 40.7 12 41.4 47 40.9 
ALL 7 8.1 0 0 7 6.1 
CML 21 24.4 3 10.3 24 20.9 
CLL 3 3.5 0 0 3 2.6 
Chemo 7 8.1 7 24.1 14 12.2 
Heart failure 1 1.2 1 3.4 2 1.7 
Septicemia 1 1.2 0 0 1 0.9 
Hemorrhage 1 1.2 0 0 1 0.9 
Facitis 1 1.2 0 0 1 0.9 
Pancreatitis 1 1.2 0 0 1 0.9 
Complicated BMT 2 2.3 0 0 2 1.7 
Hypovolemia 2 2.3 0 0 2 1.7 
Aspergillosis 1 1.2 0 0 1 0.9 
Spondylitis 1 1.2 1 3.4 1 0.9 
Lymphoma 1 1.2 0 0 1 0.9 
CVA 1 1.2 0 0 1 0.9 
Infections 0 0 1 3.4 1 0.9 
Vascular device 
infection 
0 0 1 3.4 1 0.9 
Pneumonia 0 0 1 3.4 1 0.9 
Colon cancer 0 0 1 3.4 1 0.9 
Lymphproliferate 
disease 
0 0 1 3.4 1 0.9 
Total 86 100.0 28 100.0 115 100.0 
χ = 32.48, df = 21, p =0.052  
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Table 19.  Cancer Treatment of Subjects 
Hospital site 
Site A Site B Combined 
Cancer treatment 
Frequency Percent Frequency Percent Frequency Percent 
None 17 19.8 8 27.6 25 21.7 
Chemo 24 27.9 21 72.4 45 39.1 
BMT/chemo 43 50.0 0 0 43 37.4 
BMT/chemo/radiation 2 2.3 0 0 2 1.7 
Total 86 100.0 29 100.0 115 100.0 
χ = 26.76, df = 3, p <0.001 
 
The type of treatment each patient received for leukemia was also examined.  
Table 19 lists the various treatments given to patients at site A and site B.   A significant 
difference was found with a chi-square test between the two sites (p<0.001).  Site B had 
no patients who received a BMT while in the hospital, while 52.3% at site A had this 
procedure.   
 
Table 20. Total Number of Readmissions from 1997-2000 of Subjects 
Hospital site Total number of 
admits in the 4 
yr time span 
Site A Site B Combined 
N 84 29 113 
Minimum 1 1 1 
Maximum 8 11 11 
Mean 
± SD 
2.02 
(1.65) 
3.31 
(2.82) 
2.35 
(2.08) 
t-value = 2.33, df = 34.86, p = 0.026 
 
 The total number of readmissions from 1997 through 2000 is identified with 
ranges, means and standard deviations for each site in Table 20.  The results from the 
t-test indicate a significant difference between the two sites (p=0.026), with site B having 
the greater number of readmissions.    
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Dietitian Information 
 Data collected relating to the dietitian includes the risk level of the patient 
determined by dietitian or dietetic technician assessment, how the dietitian calculated 
calorie needs, percent ideal body weight, who recommended the TPN, percentage of 
needs the TPN met, if the dietitian recommended a changed in the TPN prescription, and 
if the physician made that change.   Table 21 identifies the nutritional risk level patients 
were assigned by the dietitian or dietetic technician.  The missing data reflects risk levels 
that were not given because the initial assessment was not found in the medical record.  
Chi-square test results indicate that the difference in nutritional risk level between the 
two sites was significant (p = 0.001), with site A having no patients at low risk and more 
patients at high risk than site B.  Site B had patients at low risk and fewer patients at high 
risk than site A.    
Table 21. Nutritional Risk Level of Subjects 
Hospital site Nutritional 
risk level Site A Site B Combined 
 Frequency Percent Frequency Percent Frequency Percent 
Low risk 0 0 4 13.8 4 3.5 
Moderate risk 22 25.6 6 20.7 28 24.3 
High risk 55 64.0 14 48.3 69 60.0 
Total  77 89.5 24 82.8 101 87.8 
Missing 9 10.5 5 17.2 14 12.2 
Total 86 100.0 29 100.0 115 100.0 
χ = 13.38, df = 2, p < 0.001 
 
 Dietitians and dietetic technicians calculate calorie needs either using Resting 
Energy Expenditure (REE) or calories per kilogram of body weight.  Table 22 identifies 
frequencies and percents of the calculations completed to assess calorie needs.  The row 
labeled “not completed” refers to the medical records in which no calculation of calorie 
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needs was found.  The row labeled “missing” identifies those charts in which there was 
no calculation of calorie needs and either height or weight was not available to calculate 
the needs.  A significant difference using a chi-square test was not found between the two 
sites, however REE is used more frequently at site A than at site B.   
Table 22.  Dietitian and Dietetic Technician Calculation of Calorie Needs 
Hospital site 
Site A Site B Combined 
Calculation of calorie 
needs 
Frequency Percent Frequency Percent Frequency Percent 
REE 49 57.0 14 48.3 63 54.8 
Kcal/kg 21 24.4 10 34.5 31 27.0 
Not completed 13 15.1 3 10.3 16 13.9 
Total 83 96.5 27 93.1 110 95.7 
Missing 3 3.5 2 6.9 5 4.3 
Total 86 100.0 29 100.0 115 100.0 
χ = 1.469, df = 2, p = 0.480 
   
Table 23 delineates the percent ideal body weight on admission for the subjects.   
Results from the t-test reveal that the difference in percent ideal body weight between the 
two sites was not significant.   
Table 23. Percent Ideal Body Weight of Subjects 
Hospital site Percent ideal 
body weight Site A Site B Combined 
N 84 29 113 
Minimum 72 73 72 
Maximum 185 236 236 
Mean 
± SD 
119.12 
(26.93) 
130.66 
(28.24) 
122.08 
(30.47) 
t-value = 1.50, df = 38.04, p = 0.142 
 
 The dietitian, physician, or pharmacist generally made the TPN recommendations.  
For purposes of this research, the physician and pharmacist were grouped together as the 
data to distinguish the two was not collected.  Table 24 identifies which health 
professional made the recommendation to begin TPN.  A chi-square test did not reveal 
significant differences between the sites.    
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Table 24. TPN Recommendations by Health Professional 
Hospital site 
Site A Site B Combined 
Health professional 
Frequency Percent Frequency Percent Frequency Percent 
Dietitian 9 10.5 4 13.8 13 11.5 
Physician or 
pharmacist 
75 87.2 25 86.2 100 87.0 
Total 84 97.7 29 100.0 113 98.3 
Missing 2 2.3 0 0 2 1.7 
Total 86 100.0 29 100.0 115 100.0 
χ = 0.201, df = 1, p =0.654 
 
The dietitian at times made recommendations for changes in the TPN 
prescription.  These changes were only recorded if the recommendation was made within 
three days of initial TPN administration.  Table 25 lists the frequency and percent of 
these recommendations.  Chi-square test results indicated a significance difference 
between the two sites (p<0.001), with the dietitian at site B more frequently changing 
TPN prescriptions.   
Table 25. TPN Changes Recommended by the Dietitian 
Hospital site 
Site A Site B Combined 
Did the RD change 
the prescription? 
Frequency Percent Frequency Percent Frequency Percent 
No 83 96.5 9 31.0 92 80.0 
Yes 2 2.3 20 69.0 22 19.1 
Total  85 98.8 29 100.0 114 99.1 
Missing 1 1.2 0 0 1 0.9 
Total 86 100.0 29 100.0 115 100.0 
χ = 61.61, df = 1, p <0.001  
 
Table 26 identifies whether or not dietitian recommendations were actually 
carried out by the physician.  Significance for the variable of physicians making the 
changes recommended by the dietitian was not demonstrated with a chi-square test.  At 
site A, no changes were implemented that were recommended by the dietitian, while at 
site B 45% (9 of 20) were implemented.   
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Table 26. Dietitian Recommendations Implemented by the Physician 
Hospital site 
Site A Site B Combined 
Did the physician 
make changes? 
Frequency Percent Frequency Percent Frequency Percent 
No 2 2.3 11 37.9 13 11.3 
Yes 0 0 9 31.0 9 7.8 
No changes 
recommended 
84 97.7 9 31.0 93 80.9 
Total 86 100.0 29 100.0 115 100.0 
χ = 1.52, df = 1, p = 0.217  
 
 
 The type of feeding that the subjects were transitioned to after TPN included oral 
feeding, enteral feeding, and home TPN.  Table 27 lists the transitional feedings in 
frequencies and percentages for each site.  No significant difference was found between 
the two sites with transitional feedings using a chi-square test.   
Table 27. Transitional Feeding After TPN for Subjects 
Hospital site 
Site A Site B Combined 
Type of feeding 
Frequency Percent Frequency Percent Frequency Percent 
Oral  63 73.3 20 69.0 83 72.2 
Enteral 3 3.5 1 3.4 4 3.5 
Home TPN 5 5.8 1 3.4 6 5.2 
Died on TPN 12 14.0 7 24.1 19 16.5 
Total  83 96.5 29 100.0 112 97.4 
Missing 3 3.5 0 0 3 2.6 
Total 86 100.0 29 100.0 115 100.0 
χ = 1.60, df = 3, p =0.661 
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Infections 
 Patients may acquire nosocomial infections during their stay or be admitted with 
an infection.  Data collected on these infections included whether the patient had a line 
infection as well as any other type of infections.   Table 28 describes the type of 
infections patients had by percentages.  There was a significant difference (p<0.003) 
between the two sites, with subjects at site B having more infections.  Percentages with 
no infections for the site A and site B was 50.0 and 17.2%, respectively.         
Table 28. Infections of Subjects 
Hospital site 
Site A Site B Combined 
Infections 
Frequency Percent Frequency Percent Frequency Percent 
None 43 50.0 5 17.2 48 41.7 
Pneumonia 7 8.1 5 17.2 12 10.4 
Aspergillosis 2 2.3 0 0 2 1.7 
E.coli septicemia 0 0 1 3.4 1 0.9 
Bacteremia  6 7.0 1 3.4 7 6.1 
Pseudomonas 1 1.2 0 0 1 0.9 
UTI 0 0 1 3.4 1 0.9 
Candidiasis 1 1.2 0 0 1 0.9 
Staphyloc 1 1.2 1 3.4 2 1.7 
Septicemia  7 8.1 2 6.9 9 7.8 
Combinations of 
2 or more of the 
above infections 
18 20.9 13 44.8 31 27.0 
Total 86 100.0 29 100.0 115 100.0 
χ = 51.25, df = 27, p = 0.003 
 
 
 
 77
Leukemia and Lab Values 
 Table 29 identifies the normal range of the lab values for both of the sites.    
Table 29. Normal Lab Value Ranges 
Lab Normal Range 
Albumin (Alb) 3.3-4.6 g/L 
Platelets (Plt) 150-450 109/L 
White Blood Cells (WBC) 4-11 109/L 
Total Lymphocyte Count (TLC) 20-48% 
 
Table 30 identifies the mean and range of each of the lab values categorized by 
the type of leukemia.  Results from these tables need to be read and interpreted with 
caution because medications and transfusions were not taken into account.  Medications 
and transfusions could greatly influence these lab vales.       
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 Table 30. Lab Values of the Types of Leukemia 
 Type of 
leukemia 
Serum
albumin on 
admit 
 Lowest 
serum 
albumin 
value  
g/L g/L 
Serum 
albumin on 
discharge 
 
g/L 
Platelets on 
admit 
 
 
109/L 
Lowest 
platelets 
value 
 
109/L 
Platelets on 
discharge 
 
 
109/L 
WBC on 
admit 
 
 
109/L 
Lowest 
WBC 
value 
 
109/L 
WBC on 
discharge 
 
 
109/L 
TLC on 
admit 
 
 
% 
Lowest 
TLC 
value 
 
% 
TLC on 
discharge 
 
 
% 
Mean  3.12
(0.55) 
2.29 
(0.039) 
2.61 
(0.52) 
97.34 
(85.69) 
11.73 
(11.02) 
78.81 
(92.70) 
17.77 
(43.35) 
2.34 
(14.10) 
11.13 
(20.08) 
26.03 
(23.82) 
4.96 
(5.50) 
18.26 
(24.29) 
Minimum 2.0            1.4 1.4 7.0 1.0 1.0 0.10 0.00 0.05 1.0 0.5 1.0
AML 
Maximum 4.3            2.9 3.6 473.0 91.0 434.0 298.00 115.00 136.00 97.0 33.0 100.0
Mean  2.92
(0.62) 
2.44 
(0.34) 
2.81 
(0.38) 
167.20 
(102.20) 
23.90 
(21.38) 
36.11 
(24.67) 
6.39 
(9.51) 
0.73 
(1.61) 
4.90 
(4.27) 
20.43 
(13.38) 
7.89 
(8.00) 
15.51 
(15.17) 
Minimum 2.0            2.0 2.0 12.0 10.0 2.1 1.10 0.05 0.05 2.0 1.0 4.0
ALL 
Maximum 3.8            3.2 3.3 336.0 75.0 93.0 32.80 5.20 12.80 49.0 20.0 55.0
Mean  3.27
(0.45) 
2.49 
(0.32) 
2.76 
(0.36) 
323.07 
(260.88) 
19.33 
(42.35) 
79.26 
(85.29) 
28.12 
(26.59) 
0.40 
(1.74) 
7.16 
(10.19) 
13.54 
(12.73) 
2.89 
(3.40) 
9.72 
(9.75) 
Minimum 2.4            2.0 2.0 10.0 5.0 11.0 3.10 0.00 0.05 1.0 0.5 0.5
CML 
Maximum 4.0            3.2 3.4 861.0 230.0 349.0 92.60 9.10 45.30 48.0 16.0 36.0
Mean  2.69
(0.78) 
1.89 
(0.37) 
2.27 
(0.41) 
169.46 
(132.57) 
71.10 
(87.33) 
116.30 
(103.29) 
39.23 
(50.21) 
23.93 
(50.03) 
53.78 
(107.62) 
50.27 
(38.51) 
22.11 
(32.64) 
31.67 
(31.67) 
Minimum 1.5            1.5 1.7 17.0 9.0 12.0 1.40 0.05 3.90 6.0 1.0 2.0
CLL 
Maximum 4.4            2.6 3.1 451.0 229.0 279.0 159.00 159.00 350.00 98.0 96.0 97.0
Mean  3.10
(0.58) 
2.32 
(0.40) 
2.64 
(0.48) 
163.31 
(175.35) 
19.81 
(37.42) 
78.46 
(88.75) 
21.26 
(39.31) 
3.63 
(18.90) 
13.38 
(36.70) 
24.92 
(24.60) 
6.12 
(11.34) 
17.01 
(22.10) 
Minimum 1.5            1.4 1.4 7.0 1.0 1.0 0.10 0.00 0.05 1.0 0.5 0.5
Total 
Maximum 4.4            3.2 3.6 861.0 230.0 434.0 298.00 159.00 350.00 98.0 96.0 100.0
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Other Interesting Findings 
TPN Trends from 1997 through 2000 
 Lists of patients with leukemia admitted each year from January 1997 through 
December 2000, were obtained from data analysts from the Health Information 
Management System at both sites.  From this information, trends over the four-year 
period could be developed regarding TPN usage with leukemia patients (Table 31).  
Figure 3 depicts this trend.  The percentages were developed by dividing the total number 
of patients with leukemia on TPN each year (including readmissions) by the total number 
of admissions with a diagnosis of leukemia.  Of the overall sample, including 
readmissions, TPN was administered to leukemia patients 11.8% of the time.   
Table 31. Leukemia Admissions With and Without TPN 
Hospital site Leukemia patients 
admitted by year Site A Site B 
1997 220 78 
1998 241 128 
1999 269 139 
2000 246 94 
Leukemia patients 
given TPN by year 
 
1997 4 3 
1998 0 14 
1999 40 11 
2000 71 8 
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Figure 3.  Percentages of total leukemia patients given TPN. 
 
Additional Follow Up Analyses 
 Further analyses, beyond the hypotheses, were used to examine other plausible 
outcomes.  Additional analyses included further study on dietitian involvement as well as 
the percentage of calorie and protein needs that were met by the TPN.  The percentage of 
dietitian involvement did not correlate with the length of stay; however, dietitian 
involvement did directly correlate with the duration of TPN (r =0.028, p=0.012).       
The percentages of theses calorie and protein needs met by the TPN solution is 
delineated in Table 32 and Table 33, respectively.   
Table 32. Percent of Calorie Needs Met by TPN  
Hospital site Percent of 
calorie needs 
met 
Site A Site B Combined 
N 81 29 110 
Minimum 22 64 22 
Maximum 147 135 147 
Mean 
± SD 
80.44 
(22.03) 
100.55 
(18.41) 
85.74 
(22.86) 
t-value = 4.39, df = 108, p <0.001 
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Table 33. Percent of Protein Needs Met by TPN 
Hospital site Percent of 
protein needs 
met 
Site A Site B Combined 
N 81 29 110 
Minimum 50 59 50 
Maximum 175 170 175 
Mean 
± SD 
114.49 
(27.35) 
106.56 
(30.24) 
112.40 
(28.22) 
t-value = -1.30, df=108, p =0.195 
Results from the t-test demonstrated a significant difference between the two sites 
for the percentage of calorie needs met (p<0.001).  Site B was identified as meeting more 
of the patients needs for calories.  Both of the means for calorie and protein needs met 
were close to 100% at site B, while site A was under on calorie needs and over on the 
protein needs met by the TPN.   This data should be interpreted with caution however, as 
the patient’s oral intake was not studied.  It is possible that patients at site A could be 
eating meals or snacks and therefore were not prescribed full TPN to meet their needs.  
The percent of calories and protein met from the TPN did not correlate with the 
length of stay.  The percent of protein from the TPN did not correlate with the length of 
TPN, however the percent of calories met did inversely correlate with the duration of 
TPN (r = -0.201, p = 0.036).   
To summarize, site B used TPN less with leukemia patients but appeared to be 
meeting the nutritional needs of more of those patients; whereas site A was using TPN 
with more patients, but appeared to be meeting nutritional needs of fewer that were 
receiving TPN. 
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Discussion and Conclusions 
Discussion 
Characteristics of the Study Sample 
Age of the Sample Population 
The age range of subjects in this study was 19 years to 92 years with a median age 
of 47.0 years (mean age = 47.28).  For females, the median age was 50.0 years  
(mean age = 49.76), and for males 45.0 years was the median age (mean age = 45.08).   
  When comparing the two hospital sites, according to t-test results, site B had a 
significantly older population.  Charlson et al. (1987) reported that of all the clinical and 
demographic variables only age and comorbidity were significant predictors of comorbid 
death.  For longitudinal studies it was recommended to use age as one point on the 
comorbidity index, such as each decade over age 40 would add one point to the 
comorbidity risk index.  Age was not used in this study as a point on the comorbidity 
index, but as discussed above advanced age could be another risk factor.   
Gender of the Sample Population 
  In this study, 53% of the sample was male and females represented 47% of the 
sample.  The two hospital sites were significantly different with site B having more 
females and site A having more males.      
Type of Leukemia and Stages 
 The overall sample, with both sites combined, reveals the majority of patients 
diagnosed with AML, followed by CML, CLL, and ALL with percentages of 58.3%, 
23.5%, 9.6%, and 8.7%, respectively.  A significant difference between the two sites was 
not found with the type of leukemia diagnosis.  Overall age-adjusted incidence rates from 
 83
the Surveillance, Epidemiology, and End Results (SEER) Data and the National Cancer 
Institute per 100,000 people are as follows: AML 2.5; CLL 1.8; CML 1.3; and ALL 1.3 
(The Leukemia and Lymphoma Society 2001c).  National data identifies AML as the 
most prominent type of leukemia and this was reflected in the study sample.   
 The stages of leukemia did differ significantly between the two sites.  This is 
primarily due to the fact that site B had a smaller sample size and had less of the variance 
of stages.  Site B had no patients who were in remission with AML, ALL, and no patients 
with CML in the accelerated or refractory stages.   
Comorbidity and Death 
The Charlson Comorbidity Index scores were significantly different between the 
two sites according to results from the chi-square test.  Site B had a higher mean 
comorbidity score than site A, 0.86 and 0.30, respectively.  While the Charlson 
Comorbidity Index scores differed significantly across sites, the index was not 
significantly associated with any of the outcome measures in this study.  This is probably 
due to the highly skewed distribution of scores inherent to the instrument.  Of the total 
sample with both sites included, 76% had a comorbidity score of 0.  Charlson et al. 
(1987) validated the comorbidity index on breast cancer patients.  They reported 86% of 
their population to have a comorbidity index score of 0.  Singh et al. (1997) also validated 
the Charlson Comorbidity Index on head and neck cancer patients, and found the index to 
be a valid prognostic indicator.  However, Romano, Roos and Jollis (1993) made a 
relevant point that each specific population needs to be assessed, as there may be other 
methods to measure comorbidities that would be more relevant to that population.   
Further validation of the Charlson Comorbidity Index should be conducted, especially in 
 84
larger samples to allow for statistical transformations of skewed data or other non-linear 
analyses.  Alternatively, a more sensitive index should be developed.   
 In the total sample studied, 29.6% expired during hospitalization.  Site B did have 
a greater percentage of their total leukemia patients expire, but the differential death rates 
between site A and site B were not statistically significant.  More patients dying at site B 
could be related to a significantly higher comorbidity score and older patient population.  
Results from this study using a Spearman correlation demonstrate that the Charlson 
Comorbidity Index did positively correlate with age and dying.   
 
Correlations of Dietitian Involvement and Outcome Measures  
Length of Stay 
 Dietitian involvement had an inverse non-significant correlation with length of 
stay.  Chima et al. (1997) reported that patients at risk for malnutrition had a significantly 
longer length of stay.  Length of stay did have a significant positive correlation with the 
amount of weight lost during hospitalization.  However, percent ideal body weight on 
admission and percent of calorie and protein needs met by the TPN did not significantly 
correlate with length of stay.   McEllistrum et al. (1993) demonstrated a significant 
negative correlation between the albumin level on admission and the total length of stay.  
Conversely, in this study sample, a significant positive correlation was found between 
admit albumin and length of stay, suggesting a higher albumin upon admission is not a 
predictor of a shorter length of stay.   
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Length of TPN Administration 
  A significant inverse correlation was found between dietitian involvement and 
total length in days on TPN, indicating that more involvement by dietitians is associated 
with a shorter length of TPN.  This may be due to a significant positive correlation 
between dietitian involvement and the percent of calorie needs met by the TPN.  
Increased dietitian involvement helps patients to meet their calorie needs and meeting 
calorie needs may reduce the length of TPN.   A non-significant inverse correlation was 
found between dietitian involvement and percent of protein needs met by TPN.   
Albumin and Total Lymphocyte Count 
 The differences between admit and discharge values for albumin and TLC when 
correlated with dietitian involvement demonstrated a negative non-significant correlation.  
This indicates that dietitian involvement did not positively impact these protein lab values 
during the patient’s length of stay.  Weddle et al. (1995) reported that patients on enteral 
nutrition had an odds ratio at least four times greater for maintaining serum albumin  
(+/- 1 g/L) when dietitian’s recommendations were followed then when they were not 
followed.  In this study for the total sample the physician implemented only 41% of 
recommendations made by the dietitian.   
 Both the albumin and TLC values on admission have a positive significant 
correlation with the identical lab value on discharge.  This demonstrates that nutrition 
status reflected by these lab values on admission may be the most consistent indicators of 
nutritional status on discharge.  For cancer patients receiving chemotherapy TLC may not 
be a good indicator of nutritional status.  As a result of the chemotherapy lymphocytes 
are killed, so TLC will be much lower than the recommended or normal range.     
 86
Weight Loss 
 Weight lost during the patient’s length of stay was not significantly correlated 
with dietitian involvement.  Weight loss did not significantly correlate with the percent of 
protein or calorie needs met by the TPN.  In the total sample, a mean weight loss of 1.18 
kg per person was found.  However, research has recognized that TPN for cancer patients 
receiving chemotherapy (Lees 1997) or BMT (Shike 1996) is beneficial to body weight.  
In a study done at the University of Minnesota Hospital by Weisdorf et al. (1984), it was 
identified that BMT patients who received inadequate calories experienced a significant 
weight loss without TPN compared to those patients receiving TPN.  Shike (1996) 
reported that the weight gained does not demonstrate an improvement in lean body mass 
and the gains from the TPN diminish after the TPN was stopped.   
 The dietitian involvement between the two sites was significantly different with 
more involvement at site B.  At site B, the number of days on TPN was significantly 
lower which would translate to decreased cost to the patient or payer.  Thus, dietitian 
involvement may be a cost effective intervention.    
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Conclusions 
 As reported by Splett (1996) one of the goals of outcomes research should be to 
evaluate the effectiveness of current clinical practice.  In brief this research evaluated the 
association of dietitian involvement in oncology and nutrition support with important 
outcomes.  This study examined whether dietitian involvement with leukemia patients on 
TPN improved the outcomes of length of stay, length of TPN administration, lab vales of 
albumin and total lymphocyte count, and weight loss during the hospital stay.  The results 
of the Pearson Correlation demonstrated significance only for the total number of days on 
TPN being reduced with more dietitian involvement.   Thus, the conclusion of this study 
is that dietitian involvement can lead to a shorter duration for a patient on TPN, which in 
turn reduces costs from the TPN, facilitates earlier oral intake, and reduces time for the 
development of a line infection.   
This research examined two different hospitals under one organization.  Enforcing 
standard TPN policies is challenging as site A and site B both handle patients on TPN 
differently.  In addition, the sites appear to admit patients at different stages of leukemia.  
One of the main practice differences between the two sites was the nutrition support team 
at site B.  The nutrition support team started at site B in 1986.  The team consists of a 
registered dietitian; pharmacist; consultant coordinator, consultant registered nurse, and 
consultant respiratory therapist; and liaison physician.  The team rounds one time per 
week for approximately 60 to 90 minutes, however the team does discuss patients on a 
daily basis. The written policy at site B was for dietitians to monitor the macronutrients 
and pharmacy to monitor the micronutrients.  At site A in oncology, there was not a 
nutrition support team.  Procedures at site A were for dietitians to follow TPN 
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macronutrients.  However pharmacy was following as well, therefore the dietitians leave 
much of the follow up to the pharmacists.  This of course involves another health care 
discipline and their policies and procedures, which may again be different at each site.  
Enforcing a standard of practice across the sites would involve a change in the time 
allotment from both disciplines of dietetics and pharmacy.   
The central conclusion of this study, dietitians following up on patients is 
associated with a shortened duration on TPN, is an outcome with significant implications.  
This is one indicator of the effectiveness of dietitians in oncology in the treatment of 
leukemia.   
The first recommendation for the nutrition services department at site A is to 
evaluate their TPN protocol.  Are there any obstacles that prevent dietitians from 
complying with the current protocol?  The protocol has been if pharmacy is following the 
patient on nutrition support then dietitians do not have to follow as closely.  
Communication is needed between pharmacy and the dietitians working in nutrition 
support.  Time and budget may be issues between the two disciplines.  Another issue that 
remains however is the nutrition support team.  Is there a desire or a need for a nutrition 
support team in oncology at site A?  Is it really possible to standardize practice across the 
sites?  If that is the desire of the health system a change in the protocol, time allotment 
for nutrition support dietitians, and communication with pharmacy would be needed.   
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Future Recommendations 
 The results of this study showed that dietitian involvement and follow up were 
associated with a decrease in the amount of time a patient was on total parenteral 
nutrition.  Other hypotheses investigated by this study including association with weight 
gain, reduced length of stay, and increased albumin and total lymphocyte count were 
rejected.     Albumin and TLC were the only available lab values in this study, but they 
may not be the best predictors of nutritional status, particularly among leukemia patients.  
There are so many other factors that affect these lab values such as medications, cancer 
treatment, and hydration status.  These lab values also have a longer half-life than other 
nutritional lab values that could be used.  A future recommendation for nutritional lab 
values is to use lab values with a shorter half-life such as transferrin or prealbumin, which 
would be more representative of nutritional status at that point in time.  These lab values 
would also be affected by the cancer treatment, but would be more reflective of current 
nutrition status.   
 The Charlson Comorbidity Index was validated with breast cancer patients; thus, 
this index may not be the best parameter to assess comorbidities of leukemia patients.  
From the total sample of this study, 76% had a comorbidity index of 0.  A 
recommendation for future studies is to develop a comorbidity index specific to leukemia 
patients.   
 A growing trend in outcomes research is to assess patient outcomes.  Clinical 
indicators in oncology for JCAHO membership include patients at moderate or high risk 
implementing their nutrition care plan upon discharge (Queen, Caldwell, and Balogun 
1993).   A recommendation for future research is to conduct a prospective study in which 
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patients are assessed as to how well the patient can put into practice their specific 
nutritional care plan at discharge.  This type of study could lead to demonstrating further 
outcomes of dietitian involvement.   
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Appendix A 
Charlson Comorbidity Index 
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Weighted index of comorbidity 
 
    Assigned weights  
       for diseases      Conditions 
    
     1   Myocardial infarct 
   Congestive heart failure 
   Peripheral vascular disease 
   Cerebrovascular disease 
   Dementia 
   Chronic pulmonary disease 
   Connective tissue disease 
   Ulcer disease 
   Mild liver disease 
   Diabetes 
2                              Hemiplegia 
  Moderate or severe renal disease 
  Diabetes with end organ damage 
  Any tumor 
  Leukemia 
  Lymphoma 
     3   Moderate or severe liver disease 
     6    Metastatic solid tumor 
        AIDS 
 
      
 
 
Source:  Charlson, Mary E, Peter Pompei, Kathy L Ales, and C Ronald Mackenzie. 
1987.  A new method of classifying prognostic comorbidity in longitudinal studies: 
Development and validation.  Journal of Chronic Disease 40: 373-383. 
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Appendix B 
Translation of the Charlson Comorbidity Index Into ICD-9-CM Codes
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                  Translation of Charlson comorbidity index components into ICD-9-CM codes 
Diagnostic category Number (%) 
of patients in 
study dataset 
ICD-9-CM 
codes 
Description 
410-410.9 Acute myocardial infarction Myocardial infarction 892 (3.3) 
412* Old myocardial infarction 
Congestive heart failure 595 (2.2)  428-428.9 Heart failure 
443.9* Peripheral vascular disease 
including intermittent claudication 
441.441.9* Aortic aneurysm 
785.4* Gangrene 
V43.4* Blood vessel replaced by prosthesis 
Peripheral vascular disease 698 (2.6) 
Procedure 
38.48 
Resection and replacement of lower 
limb arteries 
Cerebrovascular disease 940 (3.5) 430-438† Cerebrovascular disease 
Dementia 59 (0.2) 290-290.9* Senile and presenile dementias 
490-496* Chronic obstructive pulmonary 
disease 
500-505* Pneumoconioses 
Chronic pulmonary disease 2466 (9.1)  
506.4* Chronic respiratory conditions due 
to fumes and vapors 
710.0* Systemic lupus erythematosus 
710.1* Polymyositis 
714.0-714.2* Adult rheumatoid arthritis 
714.81* Rheumatoid lung 
Rheumatologic disease 440 (1.6) 
725* Polymyalgia rheumatica 
531-534.9 Gastric, duodenal and gastrojejunal 
ulcers 
531.4-531.7 
532.4-532.7 
533.4-533.7 
Peptic ulcer disease 544 (2.0) 
534.4-534.7 
Chronic forms of peptic ulcer 
disease* (subset of above listing) 
571.2* Alcoholic cirrhosis 
571.5* Cirrhosis without mention of 
alcohol 
571.6* Biliary cirrhosis 
Mild liver disease 54 (0.2) 
571.4-571.49* Chronic hepatitis  
250-250.3* Diabetes with or without acute 
metabolic disturbances 
Diabetes 2828 (10.4) 
250.7* Diabetes with peripheral circulatory 
disorders 
Diabetes with chronic 
complications 
74 (0.3) 250.4-250.6* Diabetes with renal, ophthalmic, or 
neurologic 
178 (0.7) 344.1* Paraplegia Hemiplegia or paraplegia 
 342-342.9* Hemiplegia 
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582-582.9* 
Chronic glomerulonephritis 
583-583.7* Nephritis and nephropathy 
585* Chronic renal failure 
586* Renal failure, unspecified 
Renal disease 123 (0.5) 
588-588.9* Disorders resulting from impaired 
renal function 
140-172.9 Malignant neoplasms‡  
174-195.8 Malignant neoplasms‡ 
Any malignancy, including 
leukemia and lymphoma 
550 (2.0) 
200-208.9 Leukemia and lymphoma 
572.2-572.8* Hepatic coma, portal hypertension, 
other sequelae of chronic liver 
disease 
Moderate or sever liver disease 11 (0.04) 
456.0-456.21* Esophageal varices 
Metastatic solid tumor 137 (0.5) 196-199.1 Secondary malignant neoplasm or 
lymph nodes and other organs 
AIDS 0 042-044.9₤ HIV infection with related specified 
conditions 
*Asterisked codes were included if listed during index or prior admissions. Other 
codes were included only if recorded prior to the index admission.   
      † Only code 438 (late effects of cerebrovascular disease) was included during an 
index admission. 
      ‡ These codes exclude skin cancer other than melanoma.  
      ₤ These ICD codes were effectively excluded from this analysis because they only  
          became effective 1 October 1986. 
 
 
 
Source:  Deyo, Richard A, Daniel C Cherkin, and Marcia A Ciol.  1992.  Adapting a 
clinical comorbidity index for use with ICD-9-CM administrative databases.  Journal of 
Clinical Epidemiology 45:613-619.    
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Practice Guidelines 
Parenteral Nutrition 
 
1. Patients who are candidates for parenteral nutrition support cannot, should not, or 
will not eat adequately to maintain their nutrient stores.  These patients are already, 
or have the potential of becoming, malnourished. (B) 
2. PPN may be used in selected patients to provide partial or total nutrition support for 
up to 2 weeks in patients who cannot ingest or absorb oral or enteral tube-delivered 
nutrients, or when central vein parenteral nutrition is not feasible. (B) 
3. TPN support is necessary when parenteral feeding is indicated for longer than 2 
weeks, peripheral venous access is limited, nutrient needs are large or fluid 
restriction is required, and the benefits of TPN support outweigh the risks. (C) 
4. Indications for HPN are the same as for hospital TPN, except that the patient's illness 
no longer requires an acute-care setting. (C) 
5. The patient/caregiver should understand the risks, costs, expected outcome, and 
benefits of HPN therapy before it is initiated. (C) 
6. HPN should be instituted and supervised by a multidisciplinary team with knowledge 
and expertise in HPN. (C) 
7. The patient/caregiver and home environment should be suitable for safe delivery and 
monitoring of HPN. (C) 
8. The patient's need for and potential benefits from HPN therapy should be reevaluated  
       periodically. (C) 
9.    Patients receiving parenteral nutrition support should be monitored by health care        
       professionals trained to detect the infectious, mechanical, metabolic, and nutritional  
       complications of intravenous feeding at an early stage.  Monitoring should be 
completed at intervals appropriate for each specific condition and setting.  
Abnormalities detected during monitoring should be treated promptly. (C)   
 
  
 
Source:  ASPEN. 1993.  Guidelines for the use of parenteral and enteral nutrition in adult 
and pediatric  patients.  Journal of Parenteral and Enteral Nutrition 17: 1SA-51SA. 
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Practice Guidelines 
Malnutrition 
 
General guidelines for the diagnosis and treatment of malnutrition include the 
following: 
1.   An effort should be made in hospitalized patients to detect actual or potential 
malnutrition at an early stage. (C) 
2.   Patients should be considered malnourished or at risk of developing malnutrition if 
they have inadequate nutrient intake for ≥7 days or if they have a weight loss ≥10% 
of their preillness body weight. (C) 
3.   The onset or development of malnutrition should be prevented or slowed by giving  
       appropriate patients optimum nutrition counseling and diets. (C) 
4. Patients who cannot maintain adequate oral intake and who are candidates for 
nutrition support should be considered for enteral tube feeding first. (C) 
5. Enteral tube feeding and parenteral nutrition should be combined when enteral 
support alone is not possible. (C) 
6. Parenteral nutrition should be used alone when enteral feeding techniques have failed 
to provide some or all of the patient's nutrient requirements or in selected conditions 
in which enteral nutrition support is contraindicated. (C) 
7. Malnutrition should be corrected at a judicious rate and overfeeding should be 
avoided. (C) 
 
 
 
Source:  ASPEN. 1993.  Guidelines for the use of parenteral and enteral nutrition in adult 
and pediatric patients.  Journal of Parenteral and Enteral Nutrition 17: 1SA-51SA. 
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Practice Guidelines 
Cancer 
 
1.   Enteral tube feeding and parenteral nutrition support may benefit some severely 
malnourished cancer patients or those in whom gastrointestinal or other toxicities are 
anticipated to preclude adequate oral nutritional intake for more than 1 week.  
Patients who are candidates for nutrition intervention under these circumstances 
should receive nutrition support, if possible, in conjunction with the initiation of 
oncologic therapy. (C) 
2. Specialized nutrition support is not routinely indicated for well-nourished or mildly 
malnourished patients undergoing surgery, chemotherapy, or radiation treatment and 
in whom adequate oral intake is anticipated. (A) 
3. TPN is unlikely to benefit patients with advanced cancer whose malignancy is 
documented as unresponsive to chemotherapy or radiation therapy. (B) 
 
 
 
Source:  ASPEN. 1993.  Guidelines for the use of parenteral and enteral nutrition in adult 
and pediatric patients.  Journal of Parenteral and Enteral Nutrition 17: 1SA-51SA. 
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Source:  Jordan, Nancy S.
Skills in Interpreting Labo
MD: American Society of
 
  Normal WBC Count and Differential  
 
   Cell Type  Normal Range 
 
tal WBC count 4800-10,800/mm3 
 
lymorphonuclear    45-73%               
utrophils                               
egs, PMNS, polys) 
 
ands (stabs)  3-5% 
 
mphocytes     20-40% 
 
onocytes  2-8% 
 
sinophils  0-4% 
 
asophils  0-1 %  
  1996.  Hematology: Red and white blood cells tests.  In Basic 
ratory Data, 2nd ed, ed Scott L Traub, 297-319.  Bethesda, 
 Health-System Pharmacists.   
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Appendix H 
Data Collection Form
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 Medical Record Review Form 
 
Site:  University     Southdale      Subject ID: ________/Admit # _____ 
Sex: Male     Female       Age:  ________  (Must be between the ages of 18 and 70) 
Type of leukemia and stage: AML    ALL  (untreated, remission, recurrent/refractory)   
                                 CML  (chronic, accelerated, blastic, refractory)   
                     CLL   (0, I, II, III, IV, refractory) 
Date of admission: _____________  
Date of discharge: _____________  Treatment received: ________________ 
LOS:    
Reason for admission (principle diagnosis):         
Charlson Comorbidity Index Score: __________________________ 
Date of initial RD/DT assessment: _____________  Risk level: ___________ 
Patients estimated nutrient needs per day from RD assessment:   
Calories: _________        Protein (g): _________         Fluid (mL): ___________ 
Did the RD use: REE  or  kcal, g pro, and g fat/kg IBW or  AB 
Body weight on admission (kg):  __________   Height: ________    %IBW: _______ 
Date of TPN initiation:            
Who recommended TPN?  RD     Physician       Other ______________ 
Who wrote the TPN prescription?  RD      Physician       Other ____________ 
What is the volume of TPN/lipids achieved?        
        
Formula Provides: _______kcals  _______g pro  _______% fat 
Non-standard additives: No    Yes 
 
Dates of RD follow up notes:  _______________       _______________       ________________ 
_______________       _______________       _______________       _______________       
_______________        _______________       _______________       _______________       
_______________       _______________       _______________       _______________       
_______________       _______________       _______________       _______________ 
(more than just a note of pharmacy following patient) 
Did the RD recommend a change in the TPN prescription? No    Yes  
If yes, date: _______ changes:_________________________________________________ 
         
Formula Provides: _______kcals  _______g pro   _______% fat 
Changes made (physician’s orders):  No    Yes 
 
Admit serum albumin (g/dL): _______   Low: ______ Discharge serum albumin (g/dL): ______ 
Admit platelets: _______                         Low: ______  Discharge platelets: ________ 
Admit WBC (µg/dL): _______               Low: _______ Discharge WBC (µg/dL): ________ 
Admit TLC (mm3): ________                 Low: _______  Discharge TLC (mm3): _________ 
Did the patient have a line infection?  No   Yes (If yes, date first noted: ____________) 
Did the patient acquire any other infection?  No   Yes (If yes, type: 
___________________________) 
 
The patient was transitioned to:  Oral             (date ________)    
                                                    Enteral         (date ________) 
                                                    Home TPN  (date ________) 
Total number of days on TPN _______            
Weight on date of discharge or the last wt taken (kg): ___________ (Date:   ) 
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